Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Tumors or cancer of the human BREAST.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Tumors or cancer of the LUNG.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
An organoplatinum compound that possesses antineoplastic activity.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Antimetabolites that are useful in cancer chemotherapy.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Organic compounds which contain platinum as an integral part of the molecule.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
A malignant epithelial tumor with a glandular organization.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Elements of limited time intervals, contributing to particular results or situations.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A decrease in the number of NEUTROPHILS found in the blood.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The forcible expulsion of the contents of the STOMACH through the MOUTH.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Transplantation of an individual's own tissue from one site to another site.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
An alkylating agent of value against both hematologic malignancies and solid tumors.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
Tumors or cancer located in bone tissue or specific BONES.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Tumors or cancer of the STOMACH.
The return of a sign, symptom, or disease after a remission.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Tumors or cancer of the LIVER.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Inorganic compounds which contain platinum as the central atom.
Surgical procedure to remove one or both breasts.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Tumors or cancer of the COLON.
A cell line derived from cultured tumor cells.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Tumors or cancer of the PERITONEUM.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Drugs used to prevent NAUSEA or VOMITING.
An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6)
Antibodies produced by a single clone of cells.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
An anthracenedione-derived antineoplastic agent.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Cyclic hydrocarbons that contain multiple rings and share one or more atoms.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
A subspecialty of internal medicine concerned with the study of neoplasms.
Tumors or cancer of the RECTUM.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Antagonist of urate oxidase.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
A general term for various neoplastic diseases of the lymphoid tissue.
Delivery of medications through the nasal mucosa.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The giving of drugs, chemicals, or other substances by mouth.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
A subnormal level of BLOOD PLATELETS.
A radiosensitive, malignant neoplasm of the testis, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. There are three variants: classical (typical), the most common type; anaplastic; and spermatocytic. The classical seminoma is composed of fairly well differentiated sheets or cords of uniform polygonal or round cells (seminoma cells), each cell having abundant clear cytoplasm, distinct cell membranes, a centrally placed round nucleus, and one or more nucleoli. In the female, a grossly and histologically identical neoplasm, known as dysgerminoma, occurs. (Dorland, 27th ed)
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Treatment that combines chemotherapy with radiotherapy.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
Clinical protocols used to inhibit the growth or spread of NEOPLASMS.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
ARTHRITIS that is induced in experimental animals. Immunological methods and infectious agents can be used to develop experimental arthritis models. These methods include injections of stimulators of the immune response, such as an adjuvant (ADJUVANTS, IMMUNOLOGIC) or COLLAGEN.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Proteins prepared by recombinant DNA technology.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Antibodies obtained from a single clone of cells grown in mice or rats.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the URINARY BLADDER.
Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.
Tumors or cancer of the MEDIASTINUM.
Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed)
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Used for excision of the urinary bladder.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Disorders of the blood and blood forming tissues.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.
Tumors or cancer of the ESOPHAGUS.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
Tumors or cancer of the NASOPHARYNX.
A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
An anti-inflammatory 9-fluoro-glucocorticoid.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. It is the counterpart of the classical seminoma of the testis, to which it is both grossly and histologically identical. Dysgerminomas comprise 16% of all germ cell tumors but are rare before the age of 10, although nearly 50% occur before the age of 20. They are generally considered of low-grade malignancy but may spread if the tumor extends through its capsule and involves lymph nodes or blood vessels. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1646)
Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. (1/4884)

Epithelial ovarian cancer (EOC) has a high mortality rate, which is due primarily to the fact that early clinical symptoms are vague and nonspecific; hence, this disease often goes undetected and untreated until in its advanced stages. Sensitive and reliable methods for detecting earlier stages of EOC are, therefore, urgently needed. Epidermal growth factor (EGF) is a ligand for EGF receptor (ErbB1); this receptor is the product of the c-erbB1 proto-oncogene. ErbB1 overexpression is common in human ovarian carcinoma-derived cell lines and tumors, in which overexpression is thought to play a critical role in tumor etiology and progression. Furthermore, ErbB1 overexpression is associated with disease recurrence and decreased patient survival. Recently, we have developed an acridinium-linked immunosorbent assay that detects a approximately 110-kDa soluble analogue of ErbB1, ie., sErbB1, in serum samples from healthy men and women (A. T. Baron, et al., J. Immunol. Methods, 219: 23-43, 1998). Here, we demonstrate that serum p110 sErbB1 levels are significantly lower in EOC patients with stage III or IV disease prior to (P < 0.0001) and shortly after (P < 0.0001) cytoreductive staging laparotomy than in healthy women of similar ages, whereas EGF levels are significantly higher than those of age-matched healthy women only in serum samples collected shortly after tumor debulking surgery (P < 0.0001). We observe that the preoperative serum sErbB1 concentration range of advanced stage EOC patients barely overlaps with the serum sErbB1 concentration range of healthy women. In addition, we show that serum sErbB1 and EGF levels changed temporally for some EOC patients who were surgically debulked of tumor and who provided a second serum sample during the course of combination chemotherapy. Finally, we observe a significant positive association between sErbB1 and EGF levels only in serum samples of EOC patients collected prior to cytoreductive surgery (correlation coefficient = 0.61968; P = 0.0027). These data suggest that epithelial ovarian tumors concomitantly affect serum sErbB1 and EGF levels. In conclusion, these data indicate that serum sErbB1 and EGF (postoperative only) levels are significantly different between EOC patients and healthy women and that altered and/or changing serum sErbB1 and EGF levels may provide important diagnostic and/or prognostic information useful for the management of patients with EOC.  (+info)

Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. (2/4884)

To determine the effectiveness of non-cross-resistant late-consolidation chemotherapy in locally advanced breast cancer (LABC) and stage IV breast cancer, we review our experience with two regimens. Between 1985 and 1991, we enrolled 56 patients with LABC, who were treated with a doxorubicin-based adjuvant regimen, followed by a late-consolidation non-cross-resistant regimen containing methotrexate, 5-fluorouracil, cisplatin, and cyclophosphamide. Between 1985 and 1996, a total of 45 patients with limited stage IV breast cancer underwent surgical excision of all evaluable disease, making them metastatic (stage IV) with no evaluable disease. Surgery was followed by a doxorubicin-containing regimen and then a late-consolidation non-cross-resistant regimen, which was either methotrexate, 5-fluorouracil, cisplatinum, and cyclophosphamide or 5-fluorouracil, mitomycin, etoposide, and cisplatin. Twenty-four patients with limited bone metastases that were unresectable were treated with a doxorubicin-containing regimen, radiation therapy to all sites of disease, and then one of the two late non-cross-resistant regimens. With a median follow-up of 84 months, 78% of patients with LABC are alive, and 68% are free of disease. After a median follow-up of 44 months, 53% of patients with stage IV with no evaluable disease are alive and free of disease. The use of non-cross-resistant late-consolidation chemotherapy is an effective strategy in the treatment of patients with LABC and selected patients with limited stage IV breast cancer.  (+info)

Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. (3/4884)

Necrosis is a common feature of invasive carcinoma of the breast and is caused by chronic ischaemia leading to infarction. Although necrosis was previously assumed to be due to a generally poor blood supply in the tumour, in this study we show that it is present in tumours with focal areas of high vascular density situated away from the actual sites of necrosis. This may account, in part, for the previous observation that necrosis is linked to poor prognosis in this disease. Highly angiogenic tumours often display blood vessel shunting from one tumour area to another, which further exacerbates ischaemia and the formation of tumour necrosis. We have recently demonstrated that high focal microphage infiltration into breast tumours is significantly associated with increased tumour angiogenesis and poor prognosis and that the macrophages accumulate in poorly vascularized, hypoxic areas within breast tumours. In order to investigate the interactions of macrophages with chronic ischaemia (as reflected by the presence of necrosis) and angiogenesis in breast tumours, we quantified the levels of these three biological parameters in a series of 109 consecutive invasive breast carcinomas. We found that the degree of tumour necrosis was correlated with both microphage infiltration (Mann-Whitney U, P-value = 0.0009; chi-square, P-value = 0.01) and angiogenesis (Mann-Whitney U P-value = 0.0008, chi square P-value = 0.03). It was also observed that necrosis was a feature of tumours possessing an aggressive phenotype, i.e. high tumour grade (chi-square, P-value < 0.001), larger size (Mann-Whitney U, P-value = 0.003) and low oestrogen receptor status (Mann-Whitney U, P-value = 0.008; chi-square, P-value < 0.008). We suggest, therefore, that aggressive tumours rapidly outgrow their vascular supply in certain areas, leading to areas of prolonged hypoxia within the tumour and, subsequently, to necrosis. This, in turn, may attract macrophages into the tumour, which then contribute to the angiogenic process, giving rise to an association between high levels of angiogenesis and extensive necrosis.  (+info)

Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. (4/4884)

PURPOSE: From 1986 to 1992, "eight-drugs-in-one-day" (8-in-1) chemotherapy both before and after radiation therapy (XRT) (54 Gy tumor/36 Gy neuraxis) was compared with vincristine, lomustine (CCNU), and prednisone (VCP) after XRT in children with untreated, high-stage medulloblastoma (MB). PATIENTS AND METHODS: Two hundred three eligible patients with an institutional diagnosis of MB were stratified by local invasion and metastatic stage (Chang T/M) and randomized to therapy. Median time at risk from study entry was 7.0 years. RESULTS: Survival and progression-free survival (PFS) +/- SE at 7 years were 55%+/-5% and 54%+/-5%, respectively. VCP was superior to 8-in-1 chemotherapy, with 5-year PFS rates of 63%+/-5% versus 45%+/-5%, respectively (P = .006). Upon central neuropathology review, 188 patients were confirmed as having MB and were the subjects for analyses of prognostic factors. Children aged 1.5 to younger than 3 years had inferior 5-year estimates of PFS, compared with children 3 years old or older (P = .0014; 32%+/-10% v 58%+/-4%, respectively). For MB patients 3 years of age or older, the prognostic effect of tumor spread (MO v M1 v M2+) on PFS was powerful (P = .0006); 5-year PFS rates were 70%+/-5%, 57%+/-10%, and 40%+/-8%, respectively. PFS distributions at 5 years for patients with M0 tumors with less than 1.5 cm2 of residual tumor, versus > or = 1.5 cm2 of residual tumor by scan, were significantly different (P = .023; 78%+/-6% v 54%+/-11%, respectively). CONCLUSION: VCP plus XRT is a superior adjuvant combination compared with 8-in-1 chemotherapy plus XRT. For patients with M0 tumors, residual tumor bulk (not extent of resection) is a predictor for PFS. Patients with M0 tumors, > or = 3 years with < or = 1.5 cm2 residual tumor, had a 78%+/-6% 5-year PFS rate. Children younger than 3 years old who received a reduced XRT dosage had the lowest survival rate.  (+info)

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. (5/4884)

PURPOSE: To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy. PATIENTS AND METHODS: Three hundred seventy-two women with breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy were randomized to receive 90 mg of pamidronate or placebo as a 2-hour intravenous infusion given in double-blind fashion every 4 weeks for 24 cycles. Patients were evaluated for skeletal complications: pathologic fractures, spinal cord compression, irradiation of or surgery on bone, or hypercalcemia. The skeletal morbidity rate (the ratio of the number of skeletal complications to the time on trial) was the primary efficacy variable. Bone pain, use of analgesics, quality of life, performance status, bone tumor response, and biochemical parameters were also evaluated. RESULTS: One hundred eighty-two patients who received pamidronate and 189 who received placebo were assessable. The skeletal morbidity rate was significantly reduced at 12, 18, and 24 cycles in patients treated with 90 mg of pamidronate (P = .028, .023, and .008, respectively). At 24 cycles, the proportion of patients having had any skeletal complication was 56% in the pamidronate group and 67% in the placebo group (P = .027). The time to the first skeletal complication was longer for patients receiving pamidronate than for those given placebo (P = .049). There was no statistical difference in survival or in objective bone response rate. Pamidronate was well tolerated. CONCLUSION: Treatment with 90 mg of pamidronate as a 2-hour intravenous infusion every 4 weeks in addition to hormonal therapy significantly reduces skeletal morbidity from osteolytic metastases.  (+info)

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. (6/4884)

PURPOSE: To evaluate the efficacy and tolerance of combined irinotecan and oxaliplatin in patients with advanced colorectal cancer pretreated with leucovorin-modulated fluoropyrimidines. PATIENTS AND METHODS: Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after discontinuing palliative chemotherapy with fluoropyrimidines/leucovorin, were enrolled onto this study. Treatment consisted of oxaliplatin 85 mg/m2 on days 1 + 15 and irinotecan 80 mg/m2 on days 1 + 8 + 15 every 4 weeks. Depending on the absolute neutrophil counts (ANC) on the day of scheduled chemotherapeutic drug administration, a 5-day course of granulocyte colony-stimulating factor (G-CSF) 5 microg/kg/d was given. RESULTS: The overall response rate was 42% for all 36 assessable patients (95% confidence interval, 26% to 59%), including two complete remissions (6%). Thirteen additional patients (36%) had stable disease, and only eight (22%) progressed. The median time to treatment failure was 7.5 months (range, 1 to 13.5+ months). After a median follow-up time of 14 months, 19 patients (53%) are still alive. Hematologic toxicity was commonly observed, although according to the ANC-adapted use of G-CSF (in 31 patients during 81 of 174 courses), it was generally mild: grade 3 and 4 granulocytopenia occurred in only five and two cases, respectively. The most frequent nonhematologic adverse reactions were nausea/emesis and diarrhea, which were rated severe in 17% and 19%, respectively. CONCLUSION: Our data suggest that the combination of irinotecan and oxaliplatin with or without G-CSF has substantial antitumor activity in patients with progressive fluoropyrimidine/leucovorin-pretreated colorectal cancer. Overall toxicity was modest, with gastrointestinal symptoms constituting the dose-limiting side effects. Further evaluation of this regimen seems warranted.  (+info)

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. (7/4884)

PURPOSE: To compare the effect of pathologic sentinel lymph node (SLN) status with that of other known prognostic factors on recurrence and survival in patients with stage I or II cutaneous melanoma. PATIENTS AND METHODS: We reviewed the records of 612 patients with primary cutaneous melanoma who underwent lymphatic mapping and SLN biopsy between January 1991 and May 1995 to determine the effects of tumor thickness, ulceration, Clark level, location, sex, and SLN pathologic status on disease-free and disease-specific survival. RESULTS: In the 580 patients in whom lymphatic mapping and SLN biopsy were successful, the SLN was positive by conventional histology in 85 patients (15%) but negative in 495 patients (85%). SLN status was the most significant prognostic factor with respect to disease-free and disease-specific survival by univariate and multiple covariate analyses. Although tumor thickness and ulceration influenced survival in SLN-negative patients, they provided no additional prognostic information in SLN-positive patients. CONCLUSION: Lymphatic mapping and SLN biopsy is highly accurate in staging nodal basins at risk for regional metastases in primary melanoma patients and identifies those who may benefit from earlier lymphadenectomy. Furthermore, pathologic status of the SLN in these patients with clinically negative nodes is the most important prognostic factor for recurrence. The information from SLN biopsy is particularly helpful in establishing stratification criteria for future adjuvant trials.  (+info)

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). (8/4884)

BACKGROUND: Neoadjuvant chemotherapy improves overall survival and renders possible breast-conserving treatment in locally advanced breast cancer. It was necessary for this method to be evaluated in operable breast tumors too large to be treated immediately by conserving surgery. Initial results of this randomized trial were published in Annals of Oncology (1991). PATIENTS AND METHODS: Women with T2 > 3 cm or T3 N0-1 M0 breast tumors were treated by either initial mastectomy followed by adjuvant chemotherapy, or neoadjuvant chemotherapy followed by adjusted locoregional treatment. Chemotherapy was the same in the two arms. The prognostic and predictive factors of response to chemotherapy were analyzed. RESULTS: Conserving treatments were performed in 63% at the end of neoadjuvant chemotherapy and this rate had decreased to 45% at the median follow-up of 124 months. Survivals are identical in the two treatment groups. Initial clinical tumor size < 40 mm, IHC-ER < 10% and Mib1 > 40% are predictive of tumor response to chemotherapy by uni- and multivariate analyses. For outcome prediction, c-erb-B2 > 0% is the independent prognostic factor for overall and metastasis-free survivals. CONCLUSION: Breast-conserving therapy can be performed in more than half of all cases without alteration of survival, despite a non-negligible rate of local recurrences.  (+info)

In our study, ERCC1 expression provided both prognostic and predictive information in patients with completely resected bladder cancer. Among patients with transitional cell carcinoma of the bladder treated with cystectomy, high tumoral expression of ERCC1 correlated with longer survival in patients without adjuvant chemotherapy and was associated with shorter survival in those with adjuvant chemotherapy. A statistically significant interaction between ERCC1 expression and adjuvant chemotherapy indicated potential benefits of adjuvant chemotherapy in patients with ERCC1-negative tumors.. To date, the role of adjuvant chemotherapy for bladder cancer has been controversial, with no Level 1 evidence supporting adjuvant chemotherapy. In fact, the available data have not demonstrated a clear benefit of adjuvant chemotherapy. Despite mounting evidence favoring neoadjuvant chemotherapy [1-3], physicians are reluctant to adopt its practice as evidenced by only 1.2% of patients with stage III bladder ...
Apart from individual chemotherapy on the basis of different pathological patterns, anti-angiogenesis therapy has been quickly developed in recent years, becoming the most effective approach to improve chemotherapeutic efficacy. The main mechanism of anti-angiogenesis drugs includes inhabiting tumor angiogenesis to postpone or inhabit the recurrence of residual tumor through reconstructing the balance of anti-angiogenesis and preventing the growth of micro-metastasis to keep it in resting stage. The effect of adjuvant chemotherapy can be promoted by increasing the drug sensitivity, and survival time can be prolonged though further delaying the time and decreasing the rate of postoperative recurrence and metastasis of tumor by anti-angiogenesis therapy combined with adjuvant chemotherapy. As more attentions are increasingly given to anti-angiogenesis drugs in postoperative adjuvant chemotherapy at present, Endostar, an anti-angiogenesis drug studied independently in China, had favorable effect in ...
Key Findings. The median number of neoadjuvant cycles of FOLFIRINOX was six.. Among the 520 patients, 343 (66.0%) received adjuvant chemotherapy, including FOLFIRINOX in 19.8%, gemcitabine-based chemotherapy in 58.6%, capecitabine in 4.1%, a combination or other agents in 13.1%, and unknown chemotherapy in 4.4%. A total of 177 patients received no adjuvant chemotherapy.. Median overall survival was 29 months in the adjuvant therapy group vs 29 months in the no adjuvant therapy group (hazard ratio [HR] = 0.99; 95% confidence interval [CI] = 0.77-1.28, P = .93). On multivariate analysis, the hazard ratio was 0.85 (95% CI = 0.35-2.10, P = .73).. On multivariate analysis, only the interaction term of nodal status with adjuvant chemotherapy was significant. Among the 50% vs 38% of patients with pathology-proven, node-positive disease, median overall survival was 26 months with adjuvant chemotherapy vs 13 months with no adjuvant chemotherapy (HR = 0.41, 95% CI = 0.22-0.75, P = .004). Among patients ...
Giuliani, F; Marco, A D.; Casazza, A M.; and Savi, G, Combination chemotherapy and surgical adjuvant chemotherapy on ms-2 sarcoma and lung metastases in mice. (1979). Subject Strain Bibliography 1979. 165 ...
TY - JOUR. T1 - Surgery and adjuvant chemotherapy use among veterans with colon cancer. T2 - Insights from a California study. AU - Hynes, Denise M.. AU - Tarlov, Elizabeth. AU - Durazo-Arvizu, Ramon. AU - Perrin, Ruth. AU - Zhang, Qiuying. AU - Weichle, Thomas. AU - Ferreira, M. Rosario. AU - Lee, Todd. AU - Benson, Al B.. AU - Bhoopalam, Nirmala. AU - Bennett, Charles L.. PY - 2010/5/20. Y1 - 2010/5/20. N2 - Purpose: US veterans have been shown to be a vulnerable population with high cancer rates, and cancer care quality in Veterans Affairs (VA) hospitals is the focus of a congressionally mandated review. We examined rates of surgery and chemotherapy use among veterans with colon cancer at VA and non-VA facilities in California to gain insight into factors associated with quality of cancer care. Methods: A retrospective cohort of incident colon cancer patients from the California Cancer Registry, who were ≥ 66 years old and eligible to use VA and Medicare between 1999 and 2001, were observed ...
TY - JOUR. T1 - Optimizing adjuvant chemotherapy in early-stage breast cancer.. AU - Perez, Edith. AU - Muss, Hyman B.. PY - 2005/12. Y1 - 2005/12. N2 - Mortality in breast cancer has declined in the past decade, owing to advances in diagnosis, surgery, radiotherapy, and systemic treatments. Adjuvant chemotherapy has had a major effect on increasing survival in women with locoregional breast cancer. Like all treatments, adjuvant chemotherapy is a work in progress, and it has evolved from single oral agents to complex multidrug regimens. The choice of regimens is not without controversy, however, and several have been shown to be more effective than others, especially in patients who are at high risk for recurrence. The taxanes paclitaxel and docetaxel (Taxotere) have been shown to be effective in the adjuvant setting, and they have also been shown to improve the outcomes in node-positive disease. Both disease-free and overall survival are greater with doxorubicin, paclitaxel, and ...
The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellul
A new study conducted by ASCO in collaboration with the American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) and published in the Journal of Clinical Oncology1 found that patients who have to travel farther to appointments are less likely to receive adjuvant chemotherapy, regardless of whether or not they are insured.. Evidence-based treatment guidelines recommend the use of adjuvant chemotherapy in many cancer patients within 90 days after surgery. But studies show that in many cases, patients do not receive it.. To explore the role geographic access to care plays, researchers compared patients travel distance, insurance status, and an areas density of oncologists to the likelihood patients received adjuvant chemotherapy within 90 days of surgery for colon cancer. The data used in the study captured about 70% of newly diagnosed cancer cases in the United States.. Of 34,694 patients in the study cohort, three-quarters (75.7%) received adjuvant chemotherapy ...
Operation is the only curative treatment for gastric cancer patients. However, the rate of recurrence is high up to 60%. The 5 years overall survival of patient at stage IIIb or more advanced stage is still poor and approximately 8-28%. Adjuvant chemotherapy is critical for improving efficacy further. Unfortunately, the optimal adjuvant regimen is not identified yet. The standard adjuvant treatments of American and European patients are not accepted widely in Asia area because of different operation procedure and patients tolerability. Results of two critical trials indicated that S-1 alone as Japanese standard adjuvant chemotherapy could not improve the survival of stage IIIb advanced stage gastric cancer patients while the Korean standard regimen XELOX could. This implied that the more intensive chemotherapy must be used for the patients with higher risk of relapse. The proportion of the stage IIIb-IIIc Chinese gastric cancer patients is much larger than that of Japan and Korean. However, no ...
Cognitive decline is among the most feared treatment-related outcomes of older adults with cancer. The majority of older patients with breast cancer self-report cognitive problems during and after chemotherapy. Prior neuroimaging research has been performed mostly in younger patients with cancer. The purpose of this study was to evaluate longitudinal changes in brain volumes and cognition in older women with breast cancer receiving adjuvant chemotherapy. Women aged ≥ 60 years with stage I-III breast cancer receiving adjuvant chemotherapy and age-matched and sex-matched healthy controls were enrolled. All participants underwent neuropsychological testing with the US National Institutes of Health (NIH) Toolbox for Cognition and brain magnetic resonance imaging (MRI) prior to chemotherapy, and again around one month after the last infusion of chemotherapy. Brain volumes were measured using Neuroreader™ software. Longitudinal changes in brain volumes and neuropsychological scores were analyzed utilizing
With very few exceptions, initial therapy for colon cancer is adequate surgical resection. Subsequent surgical and pathologic staging will dictate the need for adjuvant therapy. Currently, Stage I colon cancer patients enjoy a high cure rate after surgery alone (,80%), and there is no evidence that these patients will benefit from any adjuvant therapy. Large randomized clinical trials have been more interested in Stage II and Stage III colon cancer patients whose cure rate can be as low as 30% after surgery alone. Early chemotherapy trials for colon cancer used the chemotherapeutic agents available at the time. Eventually, fluorinated pyrimidines (5-Fluorouracil or 5-FU) were shown to have activity against metastatic colorectal cancer. This finding led to several trials evaluating 5-FU as adjuvant therapy for high risk patients after surgery (Stage II and III colon cancer). In 1988, Buyse and colleagues(4) published a meta-analysis of all randomized controlled trials of adjuvant therapy with ...
Barrett-Lee, P., Ellis, P., Bliss, J., TACT (Taxotere as Adjuvant Chemotherapy Trial) Management Group (includes John Yarnold) (2002) Duration of adjuvant chemotherapy; Anthracyclines, taxanes and novel agents - More or less. JOURNAL OF CLINICAL ONCOLOGY, 14 (4). pp. 263-266. ISSN 0732-183X ...
BACKGROUND: Although the benefit from adjuvant chemotherapy has been established clearly in patients with Stage III colon carcinoma, the degree to which elderly patients with colon carcinoma can tolerate such therapy generally has remained unknown. METHODS: The authors reviewed all patients in their Tumor Registry with Stage II and Stage III adenocarcinoma of the colon who underwent potentially curative resection for their disease at the Geisinger Medical Center between January 1990 and September 2000. One hundred twenty patients underwent complete resection of their colon carcinoma and received 5-fluorouracil-based (5-FU) adjuvant chemotherapy. RESULTS: The 5-year disease free survival rate for patients age | or =65 years (Group A) was 70% compared with 56% for patients age | 65 years (Group B) (P = 0.085). The 5-year overall survival rate for patients in Group B was 77% compared with 62% for the patients in Group A (P = 0.143). In a Cox regression model, age was not a predictor of disease free
Among the total 1,036 breast cancer cases, 190 (18.3%) were cases of TNBC. NCCN guidelines and the St. Gallen consensus conference recommend adjuvant chemotherapy for TNBC [26], although a specific regimen for such adjuvant treatment has yet to be presented. In the 190 TNBC cases of the present study, patients undergoing surgery plus adjuvant therapy had a more favorable prognosis than those receiving surgery alone, only among those with Stage II disease, suggesting that adjuvant therapy is indeed useful for TNBC patients as the NCCN recommends, and is most relevant at Stage II. In the adjuvant therapy group, both univariate and multivariate analysis showed no significant difference in prognosis between the anthracyclin-based regimen and 5FU-based regimen, although patients with the former regimen showed a trend-level improvement in prognosis over those with the latter. Larger studies might be necessary to clarify the prognoses of anthracyclin-based regimen and 5FU-based regimen.. Since reliable ...
TY - JOUR. T1 - Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907. T2 - Adherence companion study 60104. AU - Partridge, Ann H.. AU - Archer, Laura. AU - Kornblith, Alice B.. AU - Gralow, Julie. AU - Grenier, Debjani. AU - Perez, Edith. AU - Wolff, Antonio C.. AU - Wang, Xiaofei. AU - Kastrissios, Helen. AU - Berry, Donald. AU - Hudis, Clifford. AU - Winer, Eric. AU - Muss, Hyman. PY - 2010/5/10. Y1 - 2010/5/10. N2 - Purpose: Patient adherence is critical in evaluating the effectiveness of an oral therapy. We sought to measure adherence among women randomly assigned to capecitabine in a preplanned substudy of a multicenter clinical trial. Patients and Methods: Cancer and Leukemia Group B study CALGB 49907 was a randomly assigned trial comparing standard chemotherapy versus oral chemotherapy with capecitabine in patients age 65 years or older with early-stage breast cancer. We used microelectronic monitoring system (MEMS) caps ...
Ethnic and socioeconomic inequities in use of breast cancer adjuvant therapy are well documented in many countries including the USA, and are known to contribute to lower breast cancer survival among minority ethnic and socioeconomically deprived women. We investigated ethnic and socioeconomic inequities in use of adjuvant radiotherapy and chemotherapy in a cohort of women with invasive breast cancer in New Zealand. All women with newly diagnosed invasive breast cancer during 1999-2012 were identified from the Waikato Breast Cancer Register. Rates of chemotherapy use and radiotherapy use were assessed in women who were deemed to be eligible for chemotherapy (n = 1212) and radiotherapy (n = 1708) based on guidelines. Factors associated with use of chemotherapy and radiation therapy were analysed in univariate and multivariate regression models, adjusting for covariates. Overall, rates of chemotherapy and radiotherapy use were 69% (n = 836) and 87.3% (n = 1491), respectively. In the multivariate model,
Objectives: The 21-Gene Recurrence Score (RS) assay helps guide adjuvant chemotherapy use for patients with breast cancer, and is predicted to reduce overall chemotherapy use. Little is known about recent patterns of testing in the Medicare program and the impact of testing on chemotherapy use as a function of patient age. Materials and Methods: We conducted a national claims-based study of Medicare beneficiaries age ≥66 years. We assessed trends in assay use (using multivariable regression), adjuvant chemotherapy use, and associated expenditures, for all patients and for two age strata: age 66-74 years and 75-94 years. Geographic variations in assay adoption and regional-level correlation between assay and chemotherapy use were measured. Results: We identified 132,222 women who underwent breast surgery from 2008-2011. Assay use increased from 9.0% to 17.2% from 2008-2011 (p|.001), but chemotherapy use remained stable at 12.5% (p=.49). In younger patients, assay use increased from 14.3% to 23.7% (p|
Background: The potential benefit of adjuvant chemotherapy in patients with Stage IA triple negative breast cancer (TNBC) has not been defined. In general, patients with T1a and T1b lesions have not been included in adjuvant chemotherapy trials and the inclusion of T1c tumors has been limited. In this study using National Cancer Data Base (NCDB) we investigated the actual use of adjuvant chemotherapy in Stage IA TNBC patients relative to tumor size (T1a, T1b, T1c) and report their survival outcomes.. Patients and Methods: Using NCDB we evaluated a cohort of 13,065 women with TNBC diagnosed between 2010-2012 who had American Joint Committee on Cancer Stage IA (node-negative with pathological T1a, T1b or T1c) tumors. Overall survival (OS) was the primary outcome variable. Based on the tumor size, patients were stratified on receipt of adjuvant chemotherapy or not. Patients were also stratified according to receipt of adjuvant radiation, radiation with boost, or none. Other adjusted variables ...
This study is investigating low dose versus standard dose capecitabine adjuvant chemotherapy for chinese elderly patients with stage II/III colorectal
BACKGROUND/AIM: Adjuvant chemotherapy is recommended for a subgroup of colon cancer patients based on patient and tumour characteristics. Population-based data on the adoption of the prevailing guideline recommendations including the assessment of tumour mismatch repair (MMR) status are limited, while variations in treatment strategies may influence patient outcomes. Therefore, the aim of the study was to assess practice variation in adjuvant chemotherapy administration in colon cancer patients. PATIENTS AND METHODS: We examined the association between patient, demographic and tumour characteristics on the odds of being treated with adjuvant chemotherapy in a random sample of adult stage II-III colon cancer patients from the Dutch National Cancer Registry (2008-2015) and assessed its association with survival. RESULTS: The study population consisted of 2,044 patients of whom 18% (79 out of 450) were high-risk stage II and 65% (645 out of 997) were stage III colon cancer and received adjuvant ...
Background: Adjuvant therapy for resected pancreatic adenocarcinoma was given a category 1 NCCN recommendation in 2000, yet many patients do not receive chemotherapy after definitive surgery. Whether sociodemographic disparities exist for receipt of adjuvant chemotherapy is poorly understood. Methods: The National Cancer Database was used to identify patients diagnosed with nonmetastatic pancreatic adenocarcinoma who underwent definitive surgery from 2004 through 2015. Multivariable logistic regression defined the adjusted odds ratio (aOR) and associated 95% CI of receipt of adjuvant chemotherapy. Among patients receiving chemotherapy, multivariable logistic regression assessed the odds of treatment with multiagent chemotherapy. Results: Among 18,463 patients, 11,288 (61.1%) received any adjuvant chemotherapy. Sociodemographic factors inversely associated with receipt of any adjuvant chemotherapy included uninsured status (aOR, 0.61; 95% CI, 0.50-0.74), Medicaid insurance (aOR, 0.66; 95% CI, ...
The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Among them, group A was composed of twelve patients who relapsed after surgery plus adjuvant chemotherapy and group B wa...
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
Shiroda (capecitabine) can be used for adjuvant chemotherapy after breast cancer surgery?,Patients: 5.10 underwent total resection and left breast sentinel, pathology showed 3 infiltrating ductal carcinoma, tumor diameter 1.5cm, n
Although there has been some progress in chemotherapy for metastatic gastric cancer, no standard regimen of adjuvant chemotherapy is available, and many
Based on the results of 3 adjuvant trials (MOSAIC,20 NSABP-C-07,21 and XELOXA22), oxaliplatin-based combinational chemotherapy is considered the standard of care for patients with stage III colon cancer, offering a 4% overall survival (OS) benefit over 5FU/LV at 6 years. However, the additional benefit of oxaliplatin in older patients appears to be attenuated. Subset analyses of MOSAIC and NSABP C-07 trials showed no significant benefit in OS with the addition of oxaliplatin in patients age 70 or older (MOSAIC mortality hazard ratio [HR] = 1.10; 95% confidence interval [CI], 0.73-1.65; for NSABP-C-07, HR = 1.32; 95% CI, 1.03-1.70).20,21 In contrast, a subgroup analysis of XELOXA, a study that evaluated the use of oral capecitabine in combination with oxaliplatin versus bolus 5FU/LV, the benefits of disease-free survival (DFS) were maintained regardless of age, but no significant OS benefit was shown.22 In an analysis using the ACCENT23 database of 2575 patients age ≥70 years using ...
Overuse of adjuvant chemotherapy in colon adenocarcinoma patients aged less than 50 years does not greatly improve their survival
Similarly claims that chemotherapy have produced increased percentage 5-year survival for other cancers, such as cancer of the large bowel1, could be attributed to poor methodology because none of these cancers exhibited a divergence between incidence and mortality rate curves over time5.. Ulrich Abel reviewed the evidence for the efficacy of chemotherapy for invasive epithelial cancer6, the types of cancer for which chemotherapy is most commonly used. He concluded that there was some evidence from randomised trials that chemotherapy increased survival only for small-cell lung cancer. Yet even here the gain in survival was measured in weeks or months.. Adjuvant chemotherapy for breast cancer It is widely claimed that adjuvant chemotherapy extends survival with late-stage breast cancer. For example, in a letter in the Sydney Morning Herald of 22 November 1996 Professor Allan Langlands claimed that the results of a meta-analysis of more than 100 trials of adjuvant systemic therapy in many ...
Sometimes a treatment may be started at a lower dose or the dose needs to be changed during treatment. There may also be times when your treatment is delayed. This can happen if your doctor thinks you are likely to have severe side effects, if you get severe side effects, if your blood counts are affected and causing delays in treatment, or if you are finding it hard to cope with the treatment. This is called a dose reduction, dose change or treatment delay. Your doctor will explain if you need any changes or delays to your treatment and the reason why. ...
TY - JOUR. T1 - Editorial Comment on. T2 - Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience. AU - Svatek, Robert S.. AU - Shariat, Shahrokh F.. PY - 2009/1. Y1 - 2009/1. UR - http://www.scopus.com/inward/record.url?scp=56249118335&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=56249118335&partnerID=8YFLogxK. U2 - 10.1016/j.eururo.2008.07.019. DO - 10.1016/j.eururo.2008.07.019. M3 - Comment/debate. C2 - 18640773. AN - SCOPUS:56249118335. VL - 55. SP - 185. EP - 186. JO - European Urology. JF - European Urology. SN - 0302-2838. IS - 1. ER - ...
This is intriguing. If how chemotherapy is administered makes even the smallest of improvements in mortality, then these are changes that can be made for patient benefit. Of course, the big question is: How does this impact how well a patient tolerates the treatment? There was no data presented on tolerability. If changing how this treatment is given makes it more difficult for patients to tolerate it, due to an increase in adverse effects, then more patients will stop treatment-and that defeats the whole purpose. Clearly, we need more data on tolerability and the effects of the treatment.. In another presentation Wednesday morning, Dr. Wolfgang Janni from the University of Ulm presented on the results of the SUCCESS trial on the use of adjuvant bisphosphonate treatment in high risk early breast cancer patients. Bisphosphonate treatment has been shown to reduce the risk of breast cancer recurrence in the bone, especially in postmenopausal women. However, there is no data showing what the optimal ...
BACKGROUND: We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS: We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS: At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0 ...
Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos and Earl, Helena M.. (2015) A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1). 306. ISSN 1741-7015 ...
ROCHESTER, Minnesota-Fluorouracil (5-FU)-based chemotherapy after surgery can be given safely to selected elderly patients with stage II/III colon cancer, and these patients derive the same benefits from the treatment as do their younger counterparts, according to results of a pooled analysis of seven clinical trials. 1
TY - JOUR. T1 - Estimating regimen-specific costs of chemotherapy for breast cancer. T2 - Observational cohort study. AU - Giordano, Sharon H.. AU - Niu, Jiangong. AU - Chavez-MacGregor, Mariana. AU - Zhao, Hui. AU - Zorzi, Daria. AU - Shih, Ya Chen Tina. AU - Smith, Benjamin D.. AU - Shen, Chan. PY - 2016/11/15. Y1 - 2016/11/15. N2 - BACKGROUND: One goal for high-quality patient care is communicating treatment costs to patients, yet cost information can be elusive. This is especially relevant for breast cancer care, for which numerous guideline-concordant adjuvant chemotherapy regimens exist. The objective of the current study was to generate cost estimates for such regimens from payers and patients perspectives in a large, insured US population. METHODS: Adult women who had incident breast cancer diagnosed between 2008 and 2012 (from the MarketScan database), had no secondary malignancy within 1 year of diagnosis, and received chemotherapy within 3 months of diagnosis were included (n = ...
Chemotherapy involves using anti-cancer (cytotoxic) drugs to kill the cancer cells. Chemotherapy is usually used after surgery to destroy any cancer cells that have not been removed. This is called adjuvant chemotherapy. In some cases, you may have chemotherapy before surgery, which is generally used to shrink a large tumour. This is called neo-adjuvant chemotherapy.. Several different drugs are used for chemotherapy and often three are given at once. The choice of drugs and the combination depends on the type of breast cancer and how much it has spread.. Chemotherapy is usually given as an outpatient treatment, which means you will not have to stay in hospital overnight. The drugs are usually given through a drip straight into the blood through a vein. In some cases, you may be given tablets that you can take at home. You may receive chemotherapy sessions once every two to three weeks, over a period of four to eight months, to give your body a rest in between treatments.. The main side effects ...
Chemotherapy involves using anti-cancer (cytotoxic) drugs to kill the cancer cells. Chemotherapy is usually used after surgery to destroy any cancer cells that have not been removed. This is called adjuvant chemotherapy. In some cases, you may have chemotherapy before surgery, which is generally used to shrink a large tumour. This is called neo-adjuvant chemotherapy.. Several different drugs are used for chemotherapy and often three are given at once. The choice of drugs and the combination depends on the type of breast cancer and how much it has spread.. Chemotherapy is usually given as an outpatient treatment, which means you will not have to stay in hospital overnight. The drugs are usually given through a drip straight into the blood through a vein. In some cases, you may be given tablets that you can take at home. You may receive chemotherapy sessions once every two to three weeks, over a period of four to eight months, to give your body a rest in between treatments.. The main side effects ...
目的:分析胃癌根治术后辅助治疗的疗效和副作用。方法:2005年1月至2012年9月在本院接受综合治疗的患者,男性94例,女性62例,平均年龄58.2岁(23~84岁,中位58岁)。所有病例均为手术病理证实为胃癌,按AJCC分期第7版标准,IA期7例,IB期7例,IIA期6例,IIB期19例,IIIA25例,IIIB期34例,IIIC期44例,IV期12例,不详2例。156例均采用根治性切除。12例术后未行任何化疗,142例术后接受各种方案的化疗,其中64例采用多西紫杉醇 + 铂类 + 氟尿嘧啶类(DCF)或表阿霉素 + 铂类 + 氟尿嘧啶类(ECF)三药方案,66例采用铂类 + 氟尿嘧啶类两药方案,9例采用口服替吉奥或卡培他滨单药化疗,1例仅采用铂类 + 氟尿嘧啶类腹腔灌注,2例化疗方案不详。有28例接受术后放疗。结果:中位随访36.5月。3年总生存率为53.5%,3年局部控制率为82.0%,3年无远处转移率53.8%。单因素分析显示T分期(T1-3或T4)
This study assessed the efficacy of adjuvant capecitabine in patients with liver cancer also receiving routine supportive care. The primary measure of interest
Anthracycline-based chemotherapies are effective and are widely used as the main postoperative adjuvant chemotherapy for patients with early-stage breast cancer (1-3). However, those treatments are accompanied by a high incidence of nausea and vomiting (4,5), severely compromising the patients QOL. The use of 5HT3 receptor antagonists has become commonplace in recent years, enabling a certain level of control of these symptoms. However, fatigue and decreased physical QOL remain challenging issues in breast cancer patients receiving postoperative adjuvant chemotherapy, and methods for alleviating these symptoms are needed (9). In our earlier single-group open study, in which LEM was coadministered to breast cancer patients who were treated with the FEC75 regimen, the QOL-ACD (24) was used to evaluate the effect of LEM on the patients QOL. The results indicated that coadministration of LEM was effective in improving the patients physical scale in response to the FEC75 regimen. LEM is a BRM ...
TY - JOUR. T1 - Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. AU - OConnell, Michael J.. AU - Laurie, John A.. AU - Kahn, Michael. AU - Fitzgibbons, Robert J.. AU - Erlichman, Charles. AU - Shepherd, Lois. AU - Moertel, Charles G.. AU - Kocha, Walter I.. AU - Pazdur, Richard. AU - Wieand, H. Sam. AU - Rubin, Joseph. AU - Vukov, Allen M.. AU - Donohue, John H.. AU - Krook, James E.. AU - Figueredo, Alvaro. PY - 1998/1. Y1 - 1998/1. N2 - Purpose: This study had two major goals: (1) to assess the effectiveness of a regimen of fluorouracil (5-FU) plus levamisole plus leucovorin as postoperative surgical adjuvant therapy for patients with high-risk colon cancer, and (2) to evaluate 6 months versus 12 months of chemotherapy. Patients and Methods: Patients with poor-prognosis stage II or III colon cancer were randomly assigned to receive adjuvant chemotherapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a ...
TY - JOUR. T1 - Completion of therapy by medicare patients with stage III colon cancer. AU - Dobie, Sharon A.. AU - Baldwin, Laura Mae. AU - Dominitz, Jason A.. AU - Matthews, Barbara. AU - Billingsley, Kevin. AU - Barlow, William. PY - 2006/5/3. Y1 - 2006/5/3. N2 - Background: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer ...
The multiinstitutional osteosarcoma study (MIOS), a randomized trial of adjuvant therapy for osteosarcoma with a concurrent control group, registered 113 patients from June 1982 to August 1984. Preliminary analysis of the study indicated a significant event-free survival advantage favoring immediate adjuvant chemotherapy, (P less than .001). For patients treated with surgery alone or with surgery and adjuvant chemotherapy, the lungs were involved in more than 80% of the relapses. Patients relapsing after surgery alone tended to relapse earlier (P less than .01), had more pulmonary nodules (P less than .01), and had more frequent bilateral pulmonary involvement (P less than .01) than those treated with immediate postsurgical adjuvant chemotherapy. However, patients relapsing after treatment with surgery alone experienced a significantly longer interval to further disease progression (P less than .01) and improved survival after relapse (P = .01) when compared with patients who relapsed after ...
The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) are associated with poor prognoses in patients with gastric cancer; however, few studies have focused on the dynamic changes in these ratios during the treatment of patients with gastric cancer. Here, we assessed the clinical utility of changes in these ratios as prognostic indicators in patients with stage II or III gastric cancer who received adjuvant chemotherapy. We retrospectively reviewed 100 patients who received S-1 adjuvant chemotherapy at ≥70% of the relative dose intensity, and their NLRs and PLRs were evaluated at different times: prior to gastrectomy and upon commencement and termination of adjuvant chemotherapy. To assure the clinical utility of the changes in NLR and PLR as prognostic indicators, other clinical factors were assessed as well. Disease recurred in 35 patients as follows: lymph node metastasis (17 patients, 17.0%), peritoneal metastasis (12 patients, 12.0%), and hematogenous metastasis (6
The standard of care for resected stage II - IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin regimens. A recent meta-analysis (Lung Adjuvant Cisplatin Evaluation) showed no surv
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
In this prospective study, we showed that MMR status in colorectal cancer may predict adjuvant chemotherapy response. Thus while in general, patients with stage II or III disease who received 5-FU based adjuvant chemotherapy had a better overall survival and disease free survival, this benefit was found only in patients with MMR competent tumours. Patients with MMR deficient tumours did not have a better survival or disease free survival when they received 5-FU adjuvant chemotherapy. The results remained unchanged when we stratified according to TNM stage. Conversely, when we analysed the efficacy of treatment received according to MMR status, we found that patients with MMR deficient tumours who did not receive adjuvant chemotherapy had a slightly better survival and disease free survival than patients with MMR competent tumours, even though the analysis failed to reach statistical significance.. Several studies have evaluated the benefit of adjuvant chemotherapy according to MMR status of ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment
Among patients with Stage II or Stage III colon cancer, the Oncotype DX colon cancer test provides information about risk of cancer recurrence and may help guide treatment decisions. These results were presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.. Gene expression profiling explores the patterns of genes that are active in tumor cells. Studies suggest that gene expression may provide important information about prognosis or likely response to treatment in several types of cancer. For example, among women with early-stage, estrogen receptor-positive breast cancer, the Oncotype DX breast cancer test has been shown to predict the likelihood of cancer recurrence and the likelihood of benefit from chemotherapy. As a result, the test has been added to medical guidelines for early-stage breast cancer.. A similar test became available for colon cancer patients in 2010. The test was originally developed for use in patients with Stage II colon cancer, but has now also ...
Of 3658 patients included, 1813 (49.6%) had lymph nodes removed. Relative survival of patients with lymph node dissection (including those with lymph node metastases) was significantly better than that of patients without, also after correcting for stage, tumour grade, histology and age (89% and 82%, respectively; relative excess risk [RER], 0.64; 95% confidence interval [CI]: 0.52-0.78). There was a positive correlation between the number of removed lymph nodes and overall survival (after excluding patients with lymph node metastases). Of patients with stage I-IIA EOC who had ≥10 lymph nodes removed, there was no difference in relative survival between those who received chemotherapy and those who did not (RER, 0.51; 95% CI: 0.15-1.64). This was also true for a subgroup of patients with high-risk features (stage IC and IIA and/or tumour grade 3 and/or clear cell histology [RER, 0.90; 95% CI: 0.46-1.99 ...
The International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration found evidence to support the noninferiority of 3 versus 6 months oxaliplatin-based adjuvant therapy for capecitabine plus oxaliplatin for patients with stage III colon cancer.
Introduction: Endometrial cancer patients with high grade tumours, deep myometrial invasion or advanced stage disease have a poor prognosis. Randomised studies have demonstrated the prevention of loco-regional relapses with radiotherapy (RT) with no effect on overall survival (OS). The possible additive effect of chemotherapy (CT) remains unclear. Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were undertaken to clarify if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer. The two studies were pooled. Methods: Patients (n = 540; 534 evaluable) with operated endometrial cancer International Federation of Obstetrics and Gynaecology (FIGO) stage I-III with no residual tumour andprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy with or without sequential chemotherapy. Results: In the NSGO/EORTC study, the combined modality treatment was associated with ...
In this pharmacogenetic study, there were significant associations between a common genetic polymorphism in GSTP1 and acute hematologic toxicity but no associations with DFS. Selected polymorphisms in 3 other key genes involved in CP metabolism (CYP2B6 , CYP3A4 , and GSTA1 ) were not associated with hematologic toxicity or DFS following adjuvant therapy. Because CSFs for neutropenia prophylaxis are now commonly used in patients receiving breast cancer adjuvant chemotherapy, our findings of significant associations between the GSTP1 polymorphism and hematologic toxicity suggest that a subgroup of women may be at low risk. Thus, CSF support may not be necessary when considering the cost and potential side effects from growth factors, including bone pain and decreased bone mineral density. However, further confirmation in other data sets using archived specimens, or in a prospective trial, from patients who received CP without CSF support is required before such a strategy would be ...
Management of oesophageal cancer is associated with poor outcomes and it has become apparent that surgery alone is not sufficient to effect genuine long term survival. In the UK, it is standard practice to treat oesophageal adenocarcinoma with neo-adjuvant chemotherapy (no radiation) and surgery. One problem with this approach is the issue of those patients who do not respond. The aim of this study was to investigate biomarkers which might predict response to chemotherapy. Methods A retrospective audit was carried out on post-operative outcome after oesophagectomy from 2000 to 2006 and results compared with those from previous similar audits. Patients who received neo-adjuvant chemotherapy were identified and pre-treatment oesophageal biopsies were obtained. Immunohistochemistry was used to analyse expression ofthymidylate synthase, excision cross-complementation group 1, vascular endothelial growth factor, hypoxia-inducible factor 1 and carbonic anhydrase IX. Expression was compared with ...
Source: Yeo W, Lau TK, Kwok CC, et al. NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. BMJ Supportive & Palliative Care, 29 January 2020. DOI:10.1136/bmjspcare-2019-002037
TY - JOUR. T1 - Sociodemographic disparities in the receipt of adjuvant chemotherapy among patients with resected stage I-III pancreatic adenocarcinoma. AU - Sanford, Nina N.. AU - Aguilera, Todd A.. AU - Folkert, Michael R.. AU - Ahn, Chul. AU - Mahal, Brandon A.. AU - Zeh, Herbert. AU - Beg, Muhammad S.. AU - Mansour, John. AU - Sher, David J.. N1 - Funding Information: Disclosures: Dr. Mahal has disclosed that he receives funding from the American Society of Radiation Oncology and the Prostate Cancer Foundation. The remaining authors have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article. Publisher Copyright: © 2019 Harborside Press. All rights reserved.. PY - 2019. Y1 - 2019. N2 - Background: Adjuvant therapy for resected pancreatic adenocarcinoma was given a category 1 NCCN recommendation in 2000, yetmany patients do not receive chemotherapy after definitive surgery. Whether sociodemographic ...
Colorectal adenocarcinoma is a major cause of cancer-related morbidity and mortality in Belgium and in other western countries. Prevention implies a modification of alimentation and maybe a chronic uptake of acetylsalicylic acid. Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread. Complete resection of any Astler Coller stage C colorectal malignant tumor has to be followed by a 5-fluorouracil-based adjuvant chemotherapy. In these protocols, 5-fluorouracil is administered together with folinic acid or levamisole. The administration of an adjuvant chemotherapy could also be considered for stage BII diseases. As rectal cancers are characterized by high local relapse rates, their treatment should associate radiotherapy, given either post-surgery or preferentially pre-surgery, with resection and chemotherapy. Appropriate treatment of colorectal cancers thus requires a concerted multidisciplinary approach.
The decision to treat or not to treat a stage II colon cancer patient with adjuvant chemotherapy remains one of the most challenging areas in colorectal oncology. Currently, up to 40% of stage II patients undergo adjuvant therapy in routine clinical care (34), committing to 6 months of chemotherapy, with the associated risk of potentially serious adverse events and without a method to monitor the impact of adjuvant therapy, for an absolute risk reduction of 3 to 5%. Although multiple clinicopathological markers are now validated and can be combined to define low- and high-risk groups, only a minority of defined high-risk patients will develop recurrence. The benefit of selectively treating these patients with adjuvant therapy also remains to be conclusively proven. Diagnostic approaches that better predict the disease course in this patient population are therefore urgently required.. Here, we have taken a fundamentally different approach to address these issues. We examine postoperative blood ...
Inflammation has a critical role in the pathogenesis and progression of cancer. Recently, the derived neutrophil to lymphocyte ratio (absolute count of neutrophils divided by the absolute white cell count minus the absolute count of neutrophils; dNLR) has been shown to influence clinical outcome in various cancer entities. In this study, we analysed the dNLR with clinical outcome in stage II and III colon cancer patients. Three-hundred and seventy-two patients with stage II and III colon cancer were included in this retrospective study. Kaplan-Meier curves and multivariate Cox proportion analyses were calculated for time to recurrence (TTR) and overall survival (OS). In univariate analysis, the elevated preoperative dNLR was significantly associated with decreased TTR (hazard ratio (HR) 2.38, 95% confidence interval (CI) 1.57-3.6, P|0.001) and remained significant in multivariate analysis. Patients with dNLR |3 had a median TTR of 83 months, and patients with dNLR ⩽3 showed a median TTR of 132 months.
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy.
Aim: Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. Our aim was to assess if this molecular marker can predict benefit from 5-FU adjuvant chemotherapy. A second objective was to determine if MMR status influences short term survival.. Methods: We included 754 patients with a median follow up of 728.5 days (range 1-1097). A total of 260 patients with stage II or III tumours received 5-FU adjuvant chemotherapy, according to standard clinical criteria and irrespective of their MMR status. A tumour was considered MMR deficient when either BAT-26 showed instability or there was loss of MLH1 or MSH2 protein expression.. Results: At the end of the follow up period, 206 patients died and 120 presented with tumour recurrence. Sixty six (8.8%) patients had MMR deficient tumours. There were no significant differences in overall survival (MMR competent 72.1%; MMR deficient 78.8%; p = ...
Adjuvant therapy, also known as adjunct therapy, add-on therapy, and adjuvant care, is therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant. An adjuvant agent modifies the effect of another agent, so adjuvant therapy modifies other therapy. Neoadjuvant therapy, in contrast to adjuvant therapy, is given before the main treatment. For example, systemic therapy for breast cancer that is given before removal of a breast is considered neoadjuvant chemotherapy. The most common reason ...
Background: Inflammatory blood markers, such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), have been reported as putative prognostic factors for survival and predictive factors for pathological complete response and toxicity in cancers, however with conflicting results. Methods: We retrospectively analyzed data of 280 patients with early breast cancer receiving neo-adjuvant chemotherapy between 2005 and 2013 in our center. Neutrophil count, lymphocyte count and platelet count before treatment were collected as well as data on pathological complete response, toxicity, recurrence and survival. Results: In multivariate analysis, high PLR was an independent prognostic factor for relapse-free survival (hazard ratio [HR] = 1.91; 95%CI = 1.15-3.16; p = 0.012) and for shorter overall survival (HR = 1.83; 95%CI = 1.03-3.24; p = 0.039). NLR was an independent predictive factor for febrile neutropenia (HR = 0.28; 95%CI = 0.13-0.58; p = 0.001). In triple negative breast cancer
Breast cancer patients may experience an increased chance of survival with adjuvant chemotherapy. However dermatologic adverse effects can cause major discomfort due to physical or cosmetic problems. This study aims to describe dermatologic complications in breast cancer patients during chemotherapy.This longitudinal prospective observational study included data on women with non-metastatic breast cancer whom were treated with AC-T protocol (anthracycline, cyclophosphamide, and taxane) adjuvant chemotherapy and consecutively enrolled during two years. The study was performed in an educational and tertiary referral center. The patients information including age, body mass index (BMI), past medical history, and different dermatologic complications were collected for all participants.Of 190 enrolled women, all patients experienced alopecia, which occurred in 131 patients (68.9%) after the first cycle. Skin, mucosal, and nail involvement were respectively seen in 46 (24.2%), 51 (26.8%), and 86 ...
TY - JOUR. T1 - Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer. T2 - A Phase 2 Study. AU - Hardacre, Jeffrey M.. AU - Mulcahy, Mary. AU - Small, William. AU - Talamonti, Mark. AU - Obel, Jennifer. AU - Krishnamurthi, Smitha. AU - Rocha-Lima, Caio S.. AU - Safran, Howard. AU - Lenz, Heinz Joseph. AU - Chiorean, E. Gabriela. PY - 2013. Y1 - 2013. N2 - Background: Despite continued investigation, limited progress has been made in the adjuvant treatment of resected pancreatic cancer. Novel or targeted therapies are needed. Methods: Multi-institutional, open-label, dose-finding, phase 2 trial evaluating the use of algenpantucel-L (NewLink Genetics Corporation, Ames, IA) immunotherapy in addition to chemotherapy and chemoradiotherapy in the adjuvant setting for resected pancreatic cancer (ClinicalTrials. gov identifier, NCT00569387). The primary outcome was 12-month disease-free survival. Secondary outcomes included overall survival and toxicity. Results: ...
by Dr. Mark Lewis, CKN Social Media Editor. Every student of Ethics 101 wrestles with the trolley problem. In this moral exercise of the imagination, you are standing by train tracks watching a runaway trolley race towards 5 people who are going to be crushed unless you intercede. If you pull a lever, the trolley will divert onto a different track, where it is bound to kill one person. In this situation, is it better to be passive or active? Should you pull the lever or not?. While not quite as dramatic a scenario, a similarly freighted decision between inaction and intervention plays out in oncology clinics multiple times every day as doctors weigh the risks & benefits of adjuvant chemotherapy for cancer-free patients.. In this context, the medical oncologist is asking themselves if it is worthwhile to administer potentially toxic treatment when there is no detectable cancer. The quandary arises because, despite confident pronouncements like we got it all! after a patient undergoes an ...
Pathological complete response (pCR) after neoadjuvant (presurgery) chemotherapy was associated with significantly lower recurrence risk and higher overall survival in breast cancer patients, and pCR after neoadjuvant chemotherapy had similar association with improved outcomes among those who received additional chemotherapy following surgery (adjuvant chemotherapy) versus those who did not, according to meta-analyses of data from 52 clinical trials, presented at the 2018 San Antonio Breast Cancer Symposium.
PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) related to distant disease recurrence (DR) risk (RS%). In node-negative patients, RS can be integrated with clinicopathological parameters to derive RS-pathology-clinical (RSPC) that improves prognostic accuracy. METHODS: Data were collected on patients having clinically indicated tests with an intermediate clinical risk of distant recurrence, and for whom the decision to prescribe chemotherapy remained unclear. Correlation between RS% and RSPC scores was examined. An agreement table was constructed using risk-categorised data. Association between RS%-derived categorical risk assignments and treatment recommendation was evaluated. RESULTS: Data on 171 tests (168 patients) were available. Median DR risk by RS% was 11% (range 3-34%), by RSPC it was 15% (range 4-63%). Correlation ...
In an adjuvant breast cancer trial conducted more than 20 years ago, older patients were randomized to treatment with tamoxifen and prednisone or no adjuvant therapy. Now, at 21 years of follow-up, it is clear that disease-free and overall survival remain better for those who received treatment.
Patients with mental disorders were less likely to be aware of their own breast cancer; the lesions were often found by other people such as family, care staff, and medical staff. Breast cancer patients with mental disorders had significantly more advanced T factors and overall stage at the time of surgery than their counterparts without mental illness, more patients underwent total mastectomy, and fewer patients underwent postoperative adjuvant chemotherapy and radiation. Biological markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression were not significantly different between groups. Disease-free survival and overall survival were not significantly different between groups.. CONCLUSION ...
Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented ...
Detailed description of various breast cancer treatments is given. An operation to remove the cancer but not the breast itself, includes the various surgical methods. A complete description breast cancer chemotherapy treatment also given.
Another rationale for neoadjuvant systemic therapy is that this allows for the immediate treatment of micrometastases; however, this has not been associated with an increase in survival in most trials to date (Figs. 85-1B and 85-1C). In contrast, a major advantage is that tumor response to chemotherapy is a strong predictor of outcome. Thus neoadjuvant systemic therapy can be used as an in vivo assay of systemic therapy efficacy. This, in theory, can allow for testing of new therapy regimens in the neoadjuvant setting, allowing for shorter and smaller trials to be conducted using chemotherapy response as the primary end point. In addition, the neoadjuvant setting allows the opportunity to identify biomarkers that can predict response as well as identify pharmacodynamic markers of response, that is to say, markers that can change within the primary tumor with the administration of chemotherapy, which can be an early molecular signal of therapy activity. Although the standard of care at this point ...
Chemotherapy is a systemic method of cancer treatment, in contrast with local therapies such as surgery and radiation therapy. The drugs used in chemotherapy are able to reach most parts of the body. Therefore, chemotherapy is likely to be recommended for cancer that has already spread to other areas of the body, for tumors that occur at more than one site, or for tumors that cannot be removed surgically. It is also used when a patient has recurrent disease after initial treatment with surgery or radiation therapy.. Chemotherapy is less mutilating than surgery and helps conserve organ or limb function since anti-cancer drugs are used to act on cancer cells without direct removal of a body part.. For some cancers, chemotherapy alone can destroy all the cancer cells and cure the cancer (primary treatment). As an adjuvant treatment, chemotherapy is given prior to, or after other methods, to increase the effectiveness of cancer treatment. Most often, adjuvant chemotherapy is given after other ...
Inclusion Criteria:. Histologically confirmed solid tumor malignancy for which platinum-based chemotherapy on a 21-day cycle or 14 day cycle is being recommended. Stage I of the trial: newly diagnosed disease for which neoadjuvant or adjuvant chemotherapy is planned in the curative setting, or metastatic disease. Stage II of the trial: evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria must be present for all subjects in the randomized component of the trial- if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy. Stage I: subjects may have already received no more than 2 cycle of their platinum-based chemotherapy but should not have received other prior chemotherapy regimens with the exception of patients with metastatic disease who received neoadjuvant or adjuvant chemotherapy and that chemotherapy was completed , 6 months prior to enrollment. Stage II: subjects must have received no ...
Tagrisso was recently approved in the US for the adjuvant treatment of adult patients with early-stage EGFRm NSCLC after tumour resection with curative intent based on the ADAURA Phase III trial. This indication is under priority review in China and regulatory review in the EU; additional global submission discussions are ongoing. Tagrisso is also approved for the 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC and for the treatment of locally advanced or metastatic EGFR T790M mutation-positive NSCLC in the US, Japan, China, the EU and many other countries around the world.. Lung cancer. Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths.4 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.5 The majority of all NSCLC patients are diagnosed with advanced disease while approximately 25-30% present with resectable disease at diagnosis.6-8 ...
Introduction. Gene amplification of HER2 occurs in approximately 15% to 25% of breast cancers, resulting in overexpression of HER2 on the cell surface. Before the advent of trastuzumab (Herceptin; H), HER2 amplification was associated with a more aggressive disease course and poorer overall survival.1,2 Prognosis for patients with HER2-positive disease, defined by strong overexpression (3+) of HER2 by immunohistochemistry, or by a HER2 to chromosome 17 copy number ratio of ,2 by fluorescence in situ hybridization, dramatically improved with the advent of HER2-targeted therapy.3 Trastuzumab was approved by the FDA in 1998 in combination with chemotherapy for metastatic HER2-positive breast cancer based on an improvement in overall survival (OS) compared with, chemotherapy alone, and approved in 2006 for use in the adjuvant setting after joint analysis of interim results of National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 and North Central Cancer Treatment Group (NCCTG) 9831 ...
Jay, welcome to our forum; however it would be nicer to meet you under a different set of circumstances. Is your father being treated at a top notch cancer facility by a top notch doctor for colon cancer? This is so very important. Are they going to two prong or three prong the chemo? This means utilizing two or three different types of chemo on a low dosage level. Different chemos work better for certain cancer cells and it is wise to be getting more than one chemo so that no time is wasted on treatment. How old is your father? Has he had surgery? Believe me HOPE is very important to have; so maintain the hope and let me know how things are going. Warmly, lillian We invite you to take a look at our Album. www.angelfire.com/sc/molangels/index.html ( Very informational, good tips, Molers pictures, art work and much more.... ----- Original Message ----- From: ,[email protected], To: ,[email protected], Sent: Monday, December 25, 2000 9:54 PM Subject: Re: [MOL] chemotherapy for Stage III colon ...
mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:\\}.mw-parser-output .citation .cs1-lock-free a{background:url(//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png)no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url(//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png)no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url(//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png)no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output ...
Adjuvant chemotherapy and radiation therapyEdit. If the tumor can be removed surgically, people may receive adjuvant ... Adjuvant chemotherapy appears to be ineffective in people with completely resected tumors.[75] The role of combined ... then adjuvant therapy with radiation and possibly chemotherapy is generally recommended based on the available data.[76] ... "Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized ...
Adjuvant chemotherapy Deen, SS; Priest, AN; McLean, MA; Gill, AB; Brodie, C; Crawford, R; Latimer, J; Baldwin, P; Earl, HM; ... Adjuvant and Neoadjuvant Therapy for Breast Cancer (as defined by the US National Institutes of Health (NIH) Valentini, ... chemotherapy, immunotherapy or hormone therapy) or radiation therapy is commonly used in cancers that are locally advanced, and ... "Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer". ...
Drugs used after and in addition to surgery are called adjuvant therapy. Chemotherapy or other types of therapy prior to ... Chemotherapy. Chemotherapy is predominantly used for cases of breast cancer in stages 2-4, and is particularly beneficial in ... "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer". N. Engl. J. Med. 353 (16): 1673-84. doi: ... Modern chemotherapy developed after World War II.[160]. Prominent women who died of breast cancer include Anne of Austria, the ...
January 2016). "Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant ... Tay SK, Tan LK (January 2000). "Experience of a 2-day BEP regimen in postsurgical adjuvant chemotherapy of ovarian germ cell ... In adult women postoperative adjuvant chemotherapy is standard except for stage I /grade 1 disease. In pediatric patients, ... However, these results antedate the use of multi-agent chemotherapy. With the advent of multiagent chemotherapy after surgical ...
Hughes, F. A., Higgins, G., & Beebe, G. W. (1966). Present status of surgical adjuvant lung-cancer chemotherapy. JAMA, 196(4), ... Present status of surgical adjuvant lung-cancer chemotherapy. Bronchogenic carcinoma: factors in survival. Linkage of Wartime ...
Adjuvant chemotherapy is given after a local treatment (radiotherapy or surgery). It can be used when there is little evidence ... Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is ... Chemotherapy. A woman being treated with docetaxel chemotherapy for breast cancer. Cold mittens and wine coolers are placed on ... The term chemotherapy[edit]. The word chemotherapy without a modifier usually refers to cancer treatment, but its historical ...
Adjuvant chemotherapy refers to the use of chemotherapy after apparently curative surgery to improve the outcome. In NSCLC, ... Chemotherapy[edit]. The chemotherapy regimen depends on the tumor type.[6] Small-cell lung carcinoma (SCLC), even relatively ... If stage II or III disease is confirmed, adjuvant chemotherapy (including or not including postoperative radiotherapy) improves ... Chemotherapy may be combined with palliative care in the treatment of the NSCLC. In advanced cases, appropriate chemotherapy ...
Falcetta FS, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT, Rosa DD (November 2016). "Adjuvant platinum-based chemotherapy ... "Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer". The Cochrane Database of ... which then usually requires adjuvant radiation therapy), or cisplatin chemotherapy followed by hysterectomy. When cisplatin is ... In addition, chemotherapy can be used to treat cervical cancer, and has been found to be more effective than radiation alone. ...
Standard treatment is surgery with adjuvant chemotherapy and radiotherapy. As a variation, neoadjuvant chemotherapy is very ... This makes it particularly complicated to find the optimal chemotherapy. Adding a taxane to the chemotherapy appears to improve ... TNBCs are generally very susceptible to chemotherapy. In some cases, however, early complete response does not correlate with ... BRCA1-related triple-negative breast cancer appear to be particularly susceptible to chemotherapy, including platinum-based ...
the cure rate was improved from 10% to 85%. Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked ... These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, commonly ... "Adjuvant platinum-based chemotherapy for early stage cervical cancer". The Cochrane Database of Systematic Reviews. 11: ... Oun R, Moussa YE, Wheate NJ (2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton ...
October 2005). "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer". The New England Journal of Medicine. ... August 2010). "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced ... Drugs used for chemotherapy are too toxic to give to healthy individuals, which makes it difficult to perform genetic studies ... Then, in 2005, it was shown that trastuzumab is effective as an adjuvant treatment in women with early-stage breast cancer. ...
Systemic chemotherapy may be administered as additional or adjuvant treatment. Due to the increased availability of new ... some patients have experienced stability in tumor growth with systemic chemotherapy. Systemic chemotherapy is generally ... Chemotherapy (typically utilising the chemotherapeutic agent Mitomycin C) may be infused directly into the abdominal cavity ... Some surgeons also apply early post-operative intraperitonial chemotherapy (EPIC), adjunct to surgical cytoreduction and HIPEC ...
2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2+ breast cancer". N Engl J Med. 353: 1673-1684. doi:10.1056/ ... Albain, K. S.; Paik, S.; Van't Veer, L. (2009). "Prediction of adjuvant chemotherapy benefit in endocrine responsive, early ... The choice of established chemotherapy medications, if chemotherapy is needed, may also be affected by DNA assays that predict ... Adjuvant! is based on US cohorts and presents colored bar charts that display information that may assist in decisions ...
February 2013). "Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma". The Cochrane Database of ... who were treated with combination chemotherapy including Ifosfamide, were at lower risk of disease progression and death than ...
Adjuvant chemotherapy and/or radiotherapy in malignant SFT remains controversial. SFT was first mentioned in the scientific ...
"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer". The New England Journal of Medicine. 353 (16 ... adjuvant treatment of breast cancer, the treatments of metastatic HER2+ breast cancer, cardiotoxicity, as well as health care ... the National Surgical Adjuvant Breast and Bowel Project (NSABP), and the National Accreditation Program for Breast Centers. ...
Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine. 2009;360:2055-2065. Sikov ... Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine. 2015;372: ... Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients with Node-Positive Breast Cancer. JAMA. 2006;295:1658 ... assessing the use of aspirin as adjuvant therapy for node-positive breast cancer patients. Winer has authored over 250 ...
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. „N Engl J Med". 357 (18), s. 1810-1820, Nov 2007. ... Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University ... Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or ... Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation ...
Sakuramoto (1 November 2007). "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine". NEJM. 357 (18): ... in Japan for most cancers while overall survival tend to be longer in the US due to the more aggressive use of chemotherapy in ... cancer is better in Japan than the US in both patients treated with surgery alone and surgery followed by chemotherapy. Japan ...
September 2006). "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy". The New England ... ERCC1-positive NSCLC tumors do not benefit from adjuvant platinum chemotherapy. However, ERCC1-negative NSCLC tumors, ... derive substantial benefit from adjuvant cisplatin-based chemotherapy. High ERCC1 is thus a negative predictive marker, ... Olaussen KA, Mountzios G, Soria JC (July 2007). "ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell ...
2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer". New England Journal of Medicine. 353 ... 2005). "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer". New England Journal of Medicine. 353 (16): ... 2006). "Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer". N Engl J Med. 354 (8): 809-20. doi: ... It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and ...
They are treated with surgery and adjuvant platinum chemotherapy or radiation. Yolk sac tumors, formerly called endodermal ... Most germ-cell cancers have a better prognosis than other subtypes and are more sensitive to chemotherapy. They are more likely ... Clear-cell ovarian carcinomas do not typically respond well to chemotherapy and may be related to endometriosis. They represent ... Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Outcomes depend on the extent of ...
Stanojevic Z, Djordjevic B, Todorovska I, Lilic V, Zivadinovic R, Dunjic O (2008). "Risk factors and adjuvant chemotherapy in ... If the tumor has spread surgery is cytoreductive followed by radiation therapy and/or chemotherapy. The five years survival was ...
Surgical treatments are typically followed by adjuvant, usually platinum-based, chemotherapy. Radiation therapy has been ... "Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube". Gynecol Oncol. UCSF. "Gynecologic Cancer: ... the patients with advanced stage disease survived 5 years with a surgical approach followed by cisplatinum-based chemotherapy. ...
For later stages, adjuvant chemotherapy has been shown to improve patient survival. Lymphadenectomy and lymph node chemotherapy ... "Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States, J Clin Oncol, 21 (18) (2003), ... Wright, J.D.; Doan, T.; McBride, R.; Jacobson, J.S.; Hershman, D.L. (2008). "Variability in chemotherapy delivery for elderly ... Zeimet, A.G.; Reimer, D.; Concin, N.; Braun, S.; Marth, C. (2008). "Primary chemotherapy and maintenance therapy in epithelial ...
Yamamoto M, Arii S, Sugahara K, Tobe T (Mar 1996). "Adjuvant oral chemotherapy to prevent recurrence after curative resection ... Carmofur has also been used as adjuvant chemotherapy for curatively resected colorectal cancer patients in China, Japan, and ... Baehring JM, Fulbright RK (May 2008). "Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients". J ... "An Individual Patient Data Meta-analysis of Adjuvant Therapy with Carmofur in Patients with Curatively Resected Colon Cancer". ...
"Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis". European Respiratory Journal. 21 (3 ... Most such patients require adjuvant surgery for any hope of a cure. MDR-TB is widespread in Somalia, where 8.7% of newly ... Antimicrobial Agents and Chemotherapy. 53 (8): 3181-9. doi:10.1128/AAC.01577-08. PMC 2715638. PMID 19451293. Gillespie, S. H. ( ... Antimicrobial Agents and Chemotherapy. 38 (9): 2054-8. doi:10.1128/AAC.38.9.2054. PMC 284683. PMID 7811018. "FDA Press Release ...
He J, Shen J, Yang C, Jiang L, Liang W, Shi X, Xu X, He J. Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall ... Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. The Cochrane Database of Systematic Reviews. March ... 辅助化疗(英语:Adjuvant therapy)是指在進行根除型手术後再实施化疗,目的是提高疗效。对于非小细胞肺癌,手术过程中会在病灶旁淋巴结取样以辅助分期。如果确定其为肺癌II或III期
Higher tumour grades may benefit from adjuvant treatment such as platinum-based chemotherapy. Optimal debulking is used to ... Platinum-based chemotherapy is paramount to treatment of epithelial ovarian cancer. Carboplatin tends to fare better than ... There is a lack of randomized controlled trials comparing outcomes between chemotherapy and optimal debulking, so the current ... Interval debulking surgery may be employed half way through chemotherapy following primary surgery if tumour remains above 1 cm ...
... adjuvant - administration - Adult AIDS Clinical Trials Group (AACTG) - adverse drug reaction - aerosolized - AETC - ... chemotherapy - Chlamydia - chronic idiopathic demyelinating polyneuropathy (CIPD) - Circumoral paresthesia - clade - clinical ...
... is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible ... Preventive (adjuvant) doses are typically around 45-60 Gy in 1.8-2 Gy fractions (for breast, head, and neck cancers.) Many ... It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor ... This is most commonly seen in the treatment of breast cancer with wide local excision or mastectomy followed by adjuvant ...
Active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy[2]. Prognosis. 5-year survival rate 99% (US)[4] ... "Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal ... Systemic chemotherapy for prostate cancer was first studied in the 1970s. The initial regimen of cyclophosphamide and 5- ... Cryotherapy (the process of freezing the tumor), hormonal therapy, and chemotherapy may also be offered if initial treatment ...
... osteoporosis and as adjuvant therapy during cancer chemotherapy. ...
Adjuvant analgesics, also called atypical analgesics, include nefopam, orphenadrine, pregabalin, gabapentin, cyclobenzaprine, ... Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... The use of adjuvant analgesics is an important and growing part of the pain-control field and new discoveries are made ... Main article: analgesic adjuvant. Drugs that have been introduced for uses other than analgesics are also used in pain ...
... neoadjuvant chemotherapy) and post-operatively (adjuvant chemotherapy). ... "Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer". The Cochrane ... Certain people that are deemed to be higher risk may also receive adjuvant (ancillary) chemotherapy after initial surgery or ... however a wide variety of chemotherapy options exist.[41][42] These agents include both traditional chemotherapies like ...
Vinblastine and CCNU are common chemotherapy agents used to treat mast cell tumors. Toceranib and masitinib, examples of ... factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant ... such as radiation therapy or chemotherapy, may be necessary. Prednisone is often used to shrink the remaining tumor portion. H2 ...
Chemotherapy. Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents ... Bagri A, Kouros-Mehr H, Leong KG, Plowman GD (March 2010). "Use of anti-VEGF adjuvant therapy in cancer: challenges and ... The efficacy of chemotherapy depends on the type of cancer and the stage. In combination with surgery, chemotherapy has proven ... The effectiveness of chemotherapy is often limited by its toxicity to other tissues in the body. Even when chemotherapy does ...
Do not randomize antigen plus adjuvant versus adjuvant alone. The goal is to establish clinical benefit of the immunotherapy (i ... One alternative is to target patients with residual disease after surgery, radiotherapy or chemotherapy that does not harm the ... The adjuvant may have a low-level clinical effect that skews the trial, increasing the chances of a false negative. ... Selection of the appropriate adjuvant to activate antigen-presenting cells to stimulate immune responses, is required. Bacillus ...
99,0 99,1 «The introduction of 'chemotherapy' using arsphenamine - the first magic bullet»։ Journal of the Royal Society of ... 143,0 143,1 143,2 143,3 «Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens»։ Chemical Biology ... 144,0 144,1 «Bacteriophage therapy»։ Antimicrobial Agents and Chemotherapy 45 (3): 649-59։ March 2001։ PMC 90351։ PMID 11181338 ... 80,0 80,1 «The growing burden of antimicrobial resistance»։ The Journal of Antimicrobial Chemotherapy։ 62 Suppl 1 (Supplement 1 ...
Lind M.J. M.J. (2008)։ «Principles of cytotoxic chemotherapy»։ Medicine 36 (1): 19-23։ doi:10.1016/j.mpmed.2007.10.003 ... Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale»։ Trends in Molecular Medicine 16 (3): 122-32։ March 2010 ... The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy»։ Journal of Neurology, ... 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage ...
Antimicrobial Agents and Chemotherapy. September 2006, 50 (9): 3160-1. PMC 1563524 . PMID 16940118. doi:10.1128/AAC.00563-06.. ... Adjuvant)使用[210],產於香菇的香菇多糖也在日本等國被用在癌症
1977). „Intensive chemotherapy of small cell bronchogenic carcinoma". Cancer Treatment Reports 61 (3), 349-354. o. PMID 194691 ... Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among ... September). „Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non- ... small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial". Lancet ...
"Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I ... Most previous chemotherapy drugs for cancer were (relatively) nonselective in their activity. Although their exact mechanisms ... Additionally, SCLC's are typically much more sensitive to chemotherapy and/or radiation therapy than are NSCLC's. Therefore, ... and chemotherapy with or without radiotherapy for SCLC.[6][7] ... compared with etoposide plus carboplatin in chemotherapy-naive ...
Just as for chemotherapy, radiotherapy can be used in the neoadjuvant and adjuvant setting for some stages of rectal cancer. ... ChemotherapyEdit. In both cancer of the colon and rectum, chemotherapy may be used in addition to surgery in certain cases. The ... In Stage I colon cancer, no chemotherapy is offered, and surgery is the definitive treatment. The role of chemotherapy in Stage ... Typically in this setting, a number of different chemotherapy medications may be used.[19] Chemotherapy drugs for this ...
Adjuvant capecitabine plus oxaiplatin for gastric cancer after D2 gastrectomy CLASSIC: 5 zear follow-up of an open label, ... Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. ...
AdjuvantsEdit. Main article: analgesic adjuvant. Certain drugs that have been introduced for uses other than analgesics are ... Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... Adjuvant analgesics, also called atypical analgesics, include orphenadrine, mexiletine, pregabalin, gabapentin, cyclobenzaprine ...
De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive ... Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy ... Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma PMID 17054200 https://doi.org/10.1002/ ... Done Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer PMID 19588382 https://doi. ...
Singh M, O'Hagan D (1999). "Advances in vaccine adjuvants". Nat Biotechnol. 17 (11): 1075-81. PMID 10545912.. ... "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy". Immunity. 44 (2): 343-354. doi:10.1016/j.immuni. ... "Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy". Proc Am Thorac Soc. 2 (5): 445-8. ... "Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from ...
2007). „The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer". Journal of Thoracic Oncology. 2 (5): ... Le Chevalier, T (2010). „Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?". Annals of ... Wakelee, HA; Schiller JH; Gandara DR (2006). „Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: ... 1977). „Intensive chemotherapy of small cell bronchogenic carcinoma". Cancer Treatment Reports. 61 (3): 349-354. PMID 194691.. ...
people with a tumor larger than 5 cm (2 inches) that doesn't shrink very much with neoadjuvant chemotherapy ... the availability of adjuvant radiation, and the willingness of the patient to accept higher rates of tumor recurrences after ... an analysis of surgical techniques used in an international trial of adjuvant treatment among 4,700 females with early breast ... this time the doctor will explain the results and talk about further treatment if needed such as radiation and chemotherapy. ...
Vehmanen L, Elomaa I, Blomqvist C, Saarto T (February 2006). "Tamoxifen treatment after adjuvant chemotherapy has opposite ... Bruce A. Chabner; Dan L. Longo (7 December 2011). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott ... Nagar S (2010). "Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy". Advances in Experimental Medicine ... 1980 saw the publication of the first trial to show that tamoxifen given in addition to chemotherapy improved survival for ...
Adjuvant use was safe and effective in 3 trials for cancer pain, however the drug failed to meet its primary endpoint for this ... crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced ...
"Adjuvant breast disease: an evaluation of 100 symptomatic women with breast implants or silicone fluid injections." The Keio ... treated successfully by simple removal of the implant and the capsule surrounding the implant without the need for chemotherapy ... especially in women who received adjuvant external radiation therapy.[55] Moreover, besides breast reconstruction, breast ...
... (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of ... Many more side effects have been reported for conjunctive and adjuvant treatment with docetaxel as well as rare post-marketing ... Docetaxel is a cytotoxic chemotherapeutic agent.[9][22] As with all chemotherapy, adverse effects are common, and many side ... Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V (March 2013). "Cancer chemotherapy and pregnancy". J Obstet Gynaecol ...
Chemotherapy[edit]. After surgery, adjuvant chemotherapy with gemcitabine or 5-FU can be offered if the person is sufficiently ... This was the first chemotherapy drug approved by the FDA primarily for a nonsurvival clinical trial endpoint.[75] Chemotherapy ... Chemotherapy and, to a lesser extent, radiotherapy are likely to be offered to most people, whether or not surgery is possible ... Tejani MA, Saif MW (2014). "Pancreatic neuroendocrine tumors: Does chemotherapy work?". Journal of the Pancreas. 15 (2): 132-4 ...
Chemotherapy: Adjuvant chemotherapy is the use of drugs to eradicate or suppress residual disease after surgery or irradiation ... Adjuvant chemotherapy reduces the rate of recurrence of… ... In therapeutics: Chemotherapy. Adjuvant chemotherapy is the use ... Other articles where Adjuvant chemotherapy is discussed: therapeutics: ...
... Paul H. Sugarbaker and Lana Bijelic ... I. Vergote, F. Amant, K. Leunen et al., "Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view," ... E. L. Trimble, S. Thompson, M. C. Christian, and L. Minasian, "Intraperitoneal chemotherapy for women with epithelial ovarian ... P. Jacquet and P. H. Sugarbaker, "Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and ...
Pancreatic cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Evidence-based medicine Transcriptomics Precision medicine ... Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120(8):899-903CrossRefGoogle Scholar ... Adjuvant chemotherapy with gemcitabine and capecitabine in unselected patients can double 5-year overall survival to around 30 ... The aim of this article was to summarize existing evidence on neoadjuvant and adjuvant chemotherapy in PDAC with a focus on ...
Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy. Br Med J 1980; 281 :1179 ... Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy.. Br Med J 1980; 281 doi: ...
Connected Prehabilitation Program During Neo Adjuvant Chemotherapy (TRAINING). The safety and scientific validity of this study ... Patient with neo adjuvant chemotherapy (min 3 cycles, max 6 cycles),. *Capability to perform a cardiopulmonary exercise test ( ... Connected Prehabilitation Program During Neo Adjuvant Chemotherapy Official Title ICMJE Multicenter Randomized Study Comparing ... Neo Adjuvant Chemotherapy for Patients Managed for Ovarian Cancer With or Without a Connected Prehabilitation Program ...
J. A. Broeckel, P. B. Jacobsen, L. Balducci, J. Horton, and G. H. Lyman, "Quality of life after adjuvant chemotherapy for ... Psychoneuroimmunology-Based Stress Management during Adjuvant Chemotherapy for Early Breast Cancer. Jo Lynne W. Robins,1 Nancy ... In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management ... in comparison to a usual care control group among women receiving adjuvant chemotherapy for stages I-IIIA breast cancer. We ...
... developed evidence-based recommendations for adjuvant chemotherapy for stage II colon cancer. This guide for patients is based ... Adjuvant Chemotherapy for Stage II Colon Cancer. August 16, 2004. To help doctors give their patients the best possible care, ... Adjuvant chemotherapy for stage II colon cancer may lower the risk of the cancer coming back, but is also associated with ... Adjuvant therapy is additional treatment given after surgery to reduce the risk that the cancer will come back. Chemotherapy is ...
... information on adjuvant chemotherapy but do not address which patients can be spared unnecessary adjuvant chemotherapy. He ... either adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer or no immediate adjuvant chemotherapy. ( ... observed benefit of adjuvant chemotherapy primarily in nonoptimally staged patients suggests a benefit of adjuvant chemotherapy ... optimal staging was not associated with any survival benefit in patients who received adjuvant chemotherapy. Adjuvant ...
A meta-analysis concluded that adjuvant cisplatin-based therapy improved survival in resected stage IB, II, and III NSCLC. The ... Adjuvant chemotherapy has been extensively explored in NSCLC.{ref210} ... Adjuvant chemotherapy has been extensively explored in NSCLC. [210] A meta-analysis concluded that adjuvant cisplatin-based ... Outcomes After Adjuvant Platinum-based Chemotherapy in Elderly NSCLC Patients with T4 Disease. Ann Surg Oncol. 2012 Nov 1. [ ...
NAC Sparing Mastectomy After Neo-adjuvant Chemotherapy. The safety and scientific validity of this study is the responsibility ... Nipple Areolar-complex Sparing Mastectomy After Neo-adjuvant Chemotherapy: Evaluation of Local Oncologic Safety in a Cohort ... with or without treatment with neo-adjuvant chemotherapy, the selection of patients for NAC-sparing mastectomy has been made on ... one with tumor size after neoadjuvant chemotherapy and one with tumor size before neoadjuvant chemotherapy as balancing ...
Connected Prehabilitation Program During Neo Adjuvant Chemotherapy (TRAINING). The safety and scientific validity of this study ... Patient with neo adjuvant chemotherapy (min 3 cycles, max 6 cycles),. *Capability to perform a cardiopulmonary exercise test ( ... Multicenter Randomized Study Comparing Neo Adjuvant Chemotherapy for Patients Managed for Ovarian Cancer With or Without a ...
Adjuvant chemotherapy is given after surgery for early stage cancer. It aims to cure. Though potentially toxic, it has ... Adjuvant chemotherapy is given after surgery for early stage cancer. It aims to cure. Though potentially toxic, it has ... But as I lived the ordeal of adjuvant chemotherapy, I felt a growing urge to capture that experience as data and subject it to ... In sum, the lived-body strangeness of adjuvant chemotherapy is aptly captured in Staceys notion of the abject. But in my own ...
Experimental: ARM A Durvalumab/chemotherapy association Drug: ARM A Durvalumab/chemotherapy association NEO-ADJUVANT Cycle 1 : ... Cycle 1 : chemotherapy alone (day1) Cycle 2 : chemotherapy + durvalumab (day1) Cycle 3 : chemotherapy + durvalumab (day1) ... Cycle 1 : chemotherapy alone (day1) Cycle 2 : chemotherapy + durvalumab + tremelimumab (day1) Cycle 3 : chemotherapy + ... Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV). The safety and scientific validity of this study is ...
Recent developments in adjuvant chemotherapy have regenerated enthusiasm for the treatment of this tumor. Ongoing translational ... Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy Expert Rev Neurother. 2005 Sep;5(5 ... Recent developments in adjuvant chemotherapy have regenerated enthusiasm for the treatment of this tumor. Ongoing translational ...
One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women ... Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/ ... Conclusions: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival ... breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. ...
... that means you will be receiving both chemotherapy and surgery. Learn more... ... If your cancer treatment plan includes adjuvant or neoadjuvant chemotherapy, ... When are Neoadjuvant Chemotherapy and Adjuvant Chemotherapy Used?. Adjuvant chemotherapy and neoadjuvant chemotherapy are ... Side Effects of Adjuvant and Neoadjuvant Chemotherapies. The side effects of adjuvant and neoadjuvant chemotherapy are the same ...
Regardless, lets just carry on with the surgery part, and lets talk about adjuvant therapy. Teresa, do you give any adjuvant ... We know that the recurrence of the disease is so high that I try to give adjuvant treatment if I can to all the patients after ... In regard to other efforts that were then regarding chemotherapy, the 1 that was referred to again by Dr Zhu is the 1 of Dr ... I have to say that certain perplexity was brought up in regard to the use of adjuvant therapy for biliary cancer. Of that we ...
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer.. Bastarrachea J1, ... To determine whether obesity is an independent prognostic factor among women receiving adjuvant chemotherapy for lymph node- ... an indicator of poor prognosis for patients with primary breast cancer even after the administration of adjuvant chemotherapy. ... with stages II and III primary breast cancer who were treated using three consecutive postoperative adjuvant chemotherapy ...
... phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with ... CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant ... A Cox proportional hazards model was specifically designed to evaluate the interaction between chemotherapy and these genetic ... while the interaction of MSI with chemotherapy could not be determined in the absence of relapse in the MSI group treated with ...
PURPOSE: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time ... Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. ... PATIENTS AND METHODS: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant ... CONCLUSIONS: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with ...
Adjuvant" by people in Harvard Catalyst Profiles by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of ... Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. ... Peng C, Ho J, Bai HX, Huang Y, Huang RY, Yang L. Adjuvant radiotherapy and chemotherapy in early-stage diffuse large B cell ... "Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ...
A Phase II Study of Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer. Trial Phase:. Phase 2. Minimum Age:. 18 Years ... A Phase II Study of Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer ... Patients must not have received any prior chemotherapy or hormonal therapy for the. treatment of gastric cancer.. Karnofsky ... of any other cancer therapy, including cytotoxic chemotherapy, hormonal therapy, and. immunotherapy.. Active infection that in ...
... known as adjuvant chemotherapy, may not be benefiting from these drugs. ... "Adjuvant chemotherapy is a well established, but ineffective treatment in ER+ breast cancer patients aged 40 years or less . ... Article: Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients, Jos A. van ... known as adjuvant chemotherapy, may not be benefiting from these drugs. This is especially true if their tumors respond to ...
Chemotherapy, Adjuvant. Cisplatin / adverse effects, therapeutic use. Diarrhea / chemically induced, etiology. Dose ... Ten days after radiation therapy, TP regimen was administered as adjuvant chemotherapy.. RESULTS: For the experimental and ... CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and ... This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment ...
IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin ... A recent meta-analysis (Lung Adjuvant Cisplatin Evaluation) showed no surv ... However, long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in ... Chemotherapy, Adjuvant / methods. Cisplatin / administration & dosage. Humans. Lung Neoplasms / drug therapy*, pathology. ...
We conducted a retrospective review of data from 106 patients who had received adjuvant chemotherapy. The adjuvant chemotherapy ... The PNI before adjuvant chemotherapy influenced the treatment compliance with the planned chemotherapy in the OT group, but not ... it is important to identify risk factors for the continuation of adjuvant chemotherapy. In this study, we analyzed chemotherapy ... The RFS of patients with a PNI ,50 before adjuvant chemotherapy was significantly poorer than that of the patients with a PNI ≥ ...
NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.. [David W Cescon, Desmond She, ... However, improved survival with adjuvant chemotherapy in the JBR.10-randomized trial appears limited to patients with the WT ... the clinical relevance of these findings and assessed whether NRF2 activation predicts benefit from adjuvant chemotherapy in ... A gene expression signature of NRF2 pathway activation is associated with benefit from adjuvant cisplatin/vinorelbine in SCC. ...
Cancer & chemotherapy 2004-1-31 [Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal ... We conducted a joint study of different duration of drug administration for oral adjuvant chemotherapy using camphor (HCFU) ... It appears that oral adjuvant chemotherapy with HCFU is more effective when administered for 2 years than for 6 months. ...
IntroductionPolymer-based delivery systems offer innovative intra-cavity administration of drugs, with the potential to better target micro-deposits of cancer cells in brain parenchyma beyond the resected cavity. Here we evaluate clinical utility, toxicity and sustained drug release capability of a novel formulation of poly(lactic-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG) microparticles. MethodsPLGA/PEG microparticle-based matrices were molded around an ex vivo brain pseudo-resection cavity and analyzed using magnetic resonance imaging and computerized tomography. In vitro toxicity of the polymer was assessed using tumor and endothelial cells and drug release from trichostatin A-, etoposide- and methotrexate-loaded matrices was determined. To verify activity of released agents, tumor cells were seeded onto drug-loaded matrices and viability assessed. ResultsPLGA/PEG matrices can be molded around a pseudo-resection cavity wall with no polymer-related artifact on clinical scans. The polymer
What is adjuvant chemotherapy? Learn about this cancer treatment, including who may be a candidate and what to expect from the ... Adjuvant chemotherapy for breast cancer. Adjuvant chemotherapy is commonly used for breast cancer when:. *Cells have migrated ... What is adjuvant chemotherapy?. Adjuvant chemotherapy is a cancer treatment that combines different healing therapies to ... What types of cancer is adjuvant chemotherapy used for?. Adjuvant chemotherapy is mainly used for cancers in the following body ...
  • Overall, 81% of women received anthracycline-based chemotherapy. (ascopost.com)
  • Although anthracycline-based chemotherapy has produced a modest improvement in DFS and OS over CMF (cyclophosphamide/methotrexate/fluorouracil) polychemotherapy regimens ( 1 ), this benefit seems to be largely confined to the subset of patients with amplification of the erb-B2/neu or topoisomerase II α genes or overexpression of the corresponding proteins ( 2 - 6 ). (aacrjournals.org)
  • Background: Use of anthracycline-based chemotherapy in patients with early breast cancer (EBC) has been well established but is often associated with cardiotoxicity. (uni-muenchen.de)
  • A total of 47 breast cancer patients who were scheduled to receive postoperative adjuvant anthracycline‑based chemotherapy, i.e., 5‑fluorouracil (5‑FU) + cyclophosphamide + epirubicin (FEC regimen), 5‑FU + cyclophosphamide + doxorubicin/pirarubicin (FAC regimen), cyclophosphamide + doxorubicin/pirarubicin (AC regimen) and cyclophosphamide + epirubicin (EC regimen), were entered in the study. (spandidos-publications.com)
  • Thus, LEM appears to be a useful oral adjuvant for patients receiving anthracycline‑based chemotherapy. (spandidos-publications.com)
  • However, patients on anthracycline-based chemotherapy experience fatigue and a decrease in their activity and daily quality of life (QOL), and these problems may be difficult to control ( 9 - 11 ). (spandidos-publications.com)
  • Moreover, although the host immune function of breast cancer patients on chemotherapy affects the recurrence rate ( 12 ), anthracycline-based chemotherapy is reported to adversely affect immune function ( 13 ). (spandidos-publications.com)
  • Accordingly, there is a need for treatments that can maintain and/or improve the QOL and immune function of breast cancer patients receiving anthracycline-based chemotherapy. (spandidos-publications.com)
  • The study included 187 patients with TNBC, 178 of whom were treated with adjuvant chemotherapy (164 had anthracycline-based chemotherapy). (linkos.cz)
  • High BCL2 expression predicted poor outcome in TNBC treated with adjuvant anthracycline-based chemotherapy. (linkos.cz)
  • BCL2 protein was found as an independent predictor of outcome in basal-like TNBC treated with adjuvant anthracycline-based chemotherapy (Bouchalova et al. (linkos.cz)
  • This is the first study showing BCL11A copy number status as independent predictor of outcome in TNBC treated with anthracycline-based chemotherapy. (linkos.cz)
  • The standard of care for resected stage II - IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin regimens. (biomedsearch.com)
  • Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. (centerwatch.com)
  • This is based on the high rate of systemic failure-the major cause of mortality following local treatment modalities-the high response proportion to modern combination regimens, and the possibility that chemotherapy may allow organ preservation. (springer.com)
  • To identify factors predictive of sensitivity to taxane-based regimens in patients with breast cancer, we analyzed immunohistochemical markers in primary tumors of patients randomized to a taxane-based or a taxane-free adjuvant regimen. (aacrjournals.org)
  • Furthermore, there is no data on staging procedures prior to the surgical resection or type of chemotherapy regimens used. (iaslc.org)
  • High BCL2 expression predicted poor relapse free survival (RFS) in patients treated with adjuvant anthracycline-based regimens (log-rank p = 0.035, hazard ratio, HR 2.37, 95% CI 1.04-5.41) and a trend to poor overall survival (OS) (log-rank p = 0.085). (linkos.cz)
  • The co-authors of this article conducted a systematic review to investigate the long-term effects of commonly used breast cancer adjuvant chemotherapy regimens on PN (8). (deepdyve.com)
  • In another phase III clinical trial, the prevalence of persisting PN was reported as part of the toxicity profile of the investigational chemotherapy regimens (10). (deepdyve.com)
  • Most used regimens of chemotherapy in included studies were CMF (cyclophosphamide, methotrexate, and fluorouracil) or anthracycline-based. (biomedcentral.com)
  • The objective of this study was to determine whether BCL11A status predicts outcome in TNBC patients treated with adjuvant anthracycline-based regimens. (linkos.cz)
  • Peng C, Ho J, Bai HX, Huang Y, Huang RY, Yang L. Adjuvant radiotherapy and chemotherapy in early-stage diffuse large B cell lymphoma of head and neck with extranodal involvement. (harvard.edu)
  • Women under the age of forty with breast cancer who are given drugs in addition to lumpectomies or radiotherapy, known as adjuvant chemotherapy, may not be benefiting from these drugs. (science20.com)
  • Adjuvant radiotherapy improves lymph node-field control in patients at high risk of relapse after therapeutic lymphadenectomy for metastatic melanoma, an Australian-New Zealand study has confirmed. (amazonaws.com)
  • Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were undertaken to clarify if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer. (diva-portal.org)
  • 534 evaluable) with operated endometrial cancer International Federation of Obstetrics and Gynaecology (FIGO) stage I-III with no residual tumour andprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy with or without sequential chemotherapy. (diva-portal.org)
  • A remaining question for future studies is if addition of radiotherapy to chemotherapy improves the results. (diva-portal.org)
  • Patients with primary, high-grade soft tissue sarcoma of the extremities will undergo treatment of their primary tumor with either amputation or limb-sparing surgery and radiotherapy, and then be randomized to either observation or adjuvant treatment with doxorubicin and ifosfamide with mesna (with G-CSF) for five cycles beginning post-operatively. (bioportfolio.com)
  • Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by [neoadjuvant chemotherapy] should be considered-e.g., careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy. (ascopost.com)
  • The purpose of the present study is to assess the feasibility and the potential impact of adjuvant radiotherapy (RT) in a series of patients treated in one institution. (biomedcentral.com)
  • Due to this pattern, the addition of radiotherapy appears as a logical adjuvant treatment aiming to decrease loco-regional recurrence and improve survival. (biomedcentral.com)
  • This recommendation is based on the results of clinical trials, which show that patients who receive adjuvant chemotherapy have about a 4% to 5% greater chance of survival at five years after surgery, compared with patients who did not receive adjuvant chemotherapy. (cancer.net)
  • Moreover, the authors found that among patients who did not receive adjuvant chemotherapy, optimal staging was associated with a statistically significant improvement in overall and recurrence-free survival. (innovations-report.com)
  • Or, she may receive adjuvant chemotherapy after breast surgery to kill any cancer cells that may have been too small to detect during surgery to keep them from growing and spreading. (rockymountaincancercenters.com)
  • Likewise, many patients receive adjuvant chemotherapy (and its associated toxicities) and relapse and die despite it. (amazonaws.com)
  • These patients may also receive adjuvant chemotherapy-additional treatment administered after cystectomy. (cancerconnect.com)
  • Problems with attention and symptom distress are common clinical features reported by women who receive adjuvant chemotherapy for breast cancer. (mdpi.com)
  • A total of 27 studies (14 cross-sectional, 8 both cross-sectional and prospective, and 5 prospective) were included in the analyses, involving 1562 breast cancer patients who had undergone adjuvant chemotherapy and 2799 controls that included breast cancer patients who did not receive adjuvant chemotherapy. (frontiersin.org)
  • At 5 years, women who received adjuvant chemotherapy had a 9% greater overall survival and an 11% greater recurrence-free survival than women who did not receive immediate adjuvant therapy. (innovations-report.com)
  • The 5-year disease-free survival rates were 69% for women who received adjuvant chemotherapy and 57% for those who did not. (oncologynurseadvisor.com)
  • The overall survival rate was 88% for women who received adjuvant chemotherapy and 76% for those who did not. (oncologynurseadvisor.com)
  • Our sample consisted of 5003 women who received adjuvant chemotherapy. (springer.com)
  • Following upfront resection, adjuvant chemotherapy has become mandatory to prevent early tumor recurrence. (springer.com)
  • This finding suggests that adjuvant chemotherapy in early-stage ovarian cancer may work predominantly by affecting small-volume or microscopic tumor implants or metastases that remain unnoticed at the time of surgical staging," the authors write. (innovations-report.com)
  • The NAC-PC cohort was then compared to NAC patients in terms of LDFS using two different matching criteria, one with tumor size after neoadjuvant chemotherapy and one with tumor size before neoadjuvant chemotherapy as balancing covariates. (clinicaltrials.gov)
  • Recent developments in adjuvant chemotherapy have regenerated enthusiasm for the treatment of this tumor. (nih.gov)
  • Neoadjuvant chemotherapy is delivered before surgery with the goal of shrinking a tumor or stopping the spread of cancer to make surgery less invasive and more effective. (rockymountaincancercenters.com)
  • For example, a woman with invasive breast cancer or a very large tumor may undergo neoadjuvant chemotherapy to shrink a tumor before breast surgery so a lumpectomy (surgery to remove only the cancer and surrounding tissue) can be performed instead of a mastectomy (removal of the entire breast). (rockymountaincancercenters.com)
  • PATIENTS AND METHODS: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. (uptodate.com)
  • Young patients with breast cancer are currently advised to undergo courses of chemotherapy as well as removal of the tumor and/or entire breast. (science20.com)
  • Tumor stage currently is the benchmark standard use for identifying patients who would benefit from adjuvant treatment. (biomedsearch.com)
  • Adjuvant chemotherapy given to patients following underwent radical surgery for locally advanced upper tract urothelial carcinoma was associated with a significantly decreased risk of tumor recurrence. (renalandurologynews.com)
  • RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. (bioportfolio.com)
  • I came to the following conclusion in 1994: If we assume first that cancer growth is well behaved, i.e., all cancer cells in the tumor divide once and only once during a doubling time, and second that the chemotherapy drug used is 100% effective, i.e., it kills every cell that tries to divide, then therapy duration should be one doubling time. (omicsonline.org)
  • Based on my estimates in 1994 of tumor behavior and drug 5-FU (5-Fluorouracil) effectiveness, I calculated chemotherapy should ideally be used longer than 2 years. (omicsonline.org)
  • For Stage II/III rectal cancer patients, extremely early to start PAC not only might be effectively prolonging the survival, but indeed decrease the tumor-related recurrence risk, increase the quality of life and decrease chemotherapy-associated adverse reactions. (scirp.org)
  • The prevalence of circulating tumor cells (CTCs) in patients with human epidermal growth factor receptor 2 negative, hormone receptor-positive early breast cancer after adjuvant chemotherapy was compared between anthracycline-free and anthracycline-containing treatment cohorts within the Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies (SUCCESS) C trial and showed no significant difference. (uni-muenchen.de)
  • Given the proven prognostic value of circulating tumor cells (CTCs) in EBC, we compared the prevalence of CTCs after chemotherapy between both treatment arms for a preliminary efficacy assessment. (uni-muenchen.de)
  • This study demonstrates the efficacy of focal, periocular 2-DG as an adjunct to carboplatin chemotherapy to decrease both intratumoral hypoxia and tumor burden. (arvojournals.org)
  • DENVER - The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3.1 - 7 cm. (iaslc.org)
  • In the univariate analysis, the 5-year OS for patients not receiving adjuvant chemotherapy was inversely related to tumor size, decreasing from 55% in 3.1-3.9 cm to 44% in 6-7 cm. (iaslc.org)
  • The multivariate analysis, which took into account various characteristics (i.e. age, histology, type of surgery) also demonstrated benefit from adjuvant chemotherapy for all patient groups, with HR for mortality inversely related to the tumor size, ranging from 0.77 in 3.1-3.9 cm to 0.63 in 6-7 cm patient groups. (iaslc.org)
  • However, our data suggest that there is a benefit from adjuvant chemotherapy in patients with completely resected stage T2N0M0 NSCLC regardless of tumor size. (iaslc.org)
  • Assuming similar biases for the use of chemotherapy in all tumor size subgroups, the elimination of patients with early surgical mortality and the confirmed benefit from adjuvant chemotherapy in multivariable analysis, our study suggests that the postulated benefit from adjuvant chemotherapy in patients with stage T2N0M0 NSCLC may be extended to 3.1-3.9 cm tumor size. (iaslc.org)
  • Fresh-frozen tumor tissues were collected from 148 patients with TNBC stage I-III (123 out of them were treated by anthracycline-based adjuvant chemotherapy). (linkos.cz)
  • Adjuvant chemotherapy with gemcitabine and capecitabine in unselected patients can double 5-year overall survival to around 30% compared to mono-chemotherapy with either 5-fluorouracil with folinic acid or gemcitabine. (springer.com)
  • Adjuvant chemotherapy for colon cancer usually includes a drug called fluorouracil (5-FU). (cancer.net)
  • 735 patients with lymph node-positive primary breast cancer who were treated using three consecutive fluorouracil-doxorubicin-cyclophosphamide-containing adjuvant chemotherapy protocols and for whom complete data on weight, height, standard prognostic factors, and outcome were available. (nih.gov)
  • BACKGROUND: The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX). (uptodate.com)
  • PURPOSE: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. (uptodate.com)
  • Adjuvant HIPEC consisted of fluorouracil (400 mg/m(2)) and leucovorin (20 mg/m(2)) delivered intravenously followed by intraperitoneal delivery of oxaliplatin (460 mg/m(2)) for 30 min at 42 degrees C, delivered simultaneously or within 5-8 weeks after primary tumour resection. (rug.nl)
  • ROCHESTER, Minnesota Fluorouracil (5-FU)-based chemotherapy after surgery can be given safely to selected elderly patients with stage II/III colon cancer, and these patients derive the same benefits from the treatment as do their younger counterparts, according to results of a pooled analysis of seven clinical trials. (cancernetwork.com)
  • A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). (bioportfolio.com)
  • In a separate prospective study from 2007 to 2008 the single-cell gel electrophoresis (comet) assay was used to measure DNA damage in response to in vivo exposure to 5-fluorouracil (5FU) and compared with subsequent response to chemotherapy. (bl.uk)
  • Additional survival benefit from chemotherapy seems to be stage-specific: although patients with stage III (lymph-node positive) colon cancer enjoy a 10% absolute increase in 5-year survival after 6 months of fluorouracil-based chemotherapy, this same benefit has not been convincingly demonstrated in patients with stage II (node-negative) disease. (pubmedcentralcanada.ca)
  • All patients in the chemotherapy group received 30 doses of fluorouracil (370 mg/m 2 intravenously [IV]), either in six 5-d courses every 4 wk or once/wk for 30 wk. (annals.org)
  • In the first 3 y of the trial, chemotherapy patients were also randomized to receive either high-dose (175 mg) or low-dose (25 mg) L-folinic acid IV combined with fluorouracil, plus levamisole (50 mg) or placebo 3 times daily for 3 d every 2 wk for 12 courses. (annals.org)
  • In the last 6 y of the trial, all chemotherapy patients received fluorouracil plus low-dose folinic acid. (annals.org)
  • Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. (bmj.com)
  • We analyzed specimens from patients included in the Breast Cancer International Research Group (BCIRG) 001 trial, a randomized study which showed the superiority of docetaxel/doxorubicin/cyclophosphamide over fluorouracil/doxorubicin/cyclophosphamide as adjuvant therapy for node-positive operable breast cancer in terms of disease-free survival (DFS) and overall survival (OS). (aacrjournals.org)
  • The Breast Cancer International Research Group (BCIRG) 001 trial compared the standard fluorouracil-doxorubicin-cyclophosphamide (FAC) regimen to the docetaxel-doxorubicin-cyclophosphamide (TAC) regimen as adjuvant chemotherapy in 1,491 patients with axillary node-positive breast cancer. (aacrjournals.org)
  • Clinical trials suggest that use of 5-fluorouracil-based chemotherapy has a low survival benefit with a gain of only a few percent in absolute risk. (esmo.org)
  • Chemotherapy consisted of bolus cisplatin 70 mg/m(2) and a 96-hour infusion of fluorouracil 1,000 mg/m(2)/d every 3 weeks for four cycles, with the first and second cycles given concurrent to RT. (uni-bonn.de)
  • Adjuvant therapy is additional treatment given after surgery to reduce the risk that the cancer will come back. (cancer.net)
  • however, definitive data are lacking on the effectiveness of adjuvant therapy, and there is no information available about which patients may benefit the most. (innovations-report.com)
  • Selecting only high-risk patients for additional treatment can narrow the use of chemotherapy, and this approach should be used until such time as a randomized trial can demonstrate that good prognosis, early-stage patients benefit from such therapy," he writes. (innovations-report.com)
  • [ 210 ] A meta-analysis concluded that adjuvant cisplatin-based therapy improved survival in resected stage IB, II, and III NSCLC. (medscape.com)
  • This study will also allow to explore the feasibility of a salvage therapy personalized according to the results of interval surgery and type of previous neo-adjuvant therapy. (clinicaltrials.gov)
  • This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. (nih.gov)
  • Regardless, let's just carry on with the surgery part, and let's talk about adjuvant therapy. (onclive.com)
  • Teresa, do you give any adjuvant therapy for cholangiocarcinoma? (onclive.com)
  • CONCLUSIONS: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy. (uptodate.com)
  • Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. (harvard.edu)
  • Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. (harvard.edu)
  • Patients must not have received any prior chemotherapy or hormonal therapy for the treatment of gastric cancer. (knowcancer.com)
  • Concurrent administration of any other cancer therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy. (knowcancer.com)
  • Ten days after radiation therapy, TP regimen was administered as adjuvant chemotherapy. (biomedsearch.com)
  • Depending on the type of cancer, what stage the cancer is in and your overall health, your doctor may recommend chemotherapy in combination with radiation, surgery, hormone therapy, immunotherapy or targeted therapy. (mercy.com)
  • If you are in a later stage where the cancer has spread to other body parts or the lymph nodes, adjuvant therapy may be more successful. (mercy.com)
  • There's been a lot of discussion in the past few years about how much and how long adjuvant therapy should continue. (bcaction.org)
  • On Thursday, there was a presentation about another study that looked at the optimal length of time on adjuvant therapy-this time regarding adjuvant endocrine therapy for hormone receptor positive postmenopausal women. (bcaction.org)
  • He pointed out, however, that elderly patients with stage II/III colon cancer are less likely than younger patients to be offered or to receive adjuvant chemo-therapy. (cancernetwork.com)
  • Alison Birtle and Surena Matin join Ashish Kamat for an educational session on the highly debated question of "should we use neoadjuvant or adjuvant therapy when it comes to upper tract urothelial carcinoma? (urotoday.com)
  • In this case, "Should we use neoadjuvant or adjuvant therapy when it comes to upper tract urothelial carcinoma? (urotoday.com)
  • This therapy became known as metronomic chemotherapy. (omicsonline.org)
  • Stage II (basically node-negative) colon cancer is usually not given adjuvant therapy while stage III (node positive) colon cancer has higher risk of relapse and is usually given adjuvant therapy. (omicsonline.org)
  • On the other hand, there is no strong data to support adjuvant therapy (AC), as of yet - though, there are indicators to suggest it may be effective. (urotoday.com)
  • For patients who will receive adjuvant therapy, I think this does represent the new standard of care," she commented. (ascopost.com)
  • For Stage II/III rectal cancer patients, curative resection is the primary treatment, prescribing of postoperative adjuvant chemotherapy (PAC) is regarded as a standard therapy. (scirp.org)
  • Aebi recommended that physicians prescribe adjuvant chemotherapy for patients with isolated local and regional recurrence of breast cancer, especially if the recurrence is ER-negative and therefore not sensitive to endocrine therapy. (oncologynurseadvisor.com)
  • These results indicate that cisplatin is most promising for the partner of S-1 as adjuvant therapy that may reduce recurrence and improve survival of stage III gastric cancer. (ovid.com)
  • However, the occurrence of delay in the delivery of adjuvant therapy and its impact on prognosis is not well understood. (springer.com)
  • To date, there are limited recommendations about the role of NSM in patients receiving aggressive adjuvant therapy. (aacrjournals.org)
  • The purpose of this investigation is to determine whether NSM in the setting of neo-adjuvant or adjuvant chemotherapy and/or radiation therapy increased the risks for wound complications. (aacrjournals.org)
  • Multiple data points including neo-adjuvant or adjuvant chemotherapy and/or radiation therapy, obesity, smoking history, and type of reconstructive surgery were examined in detail. (aacrjournals.org)
  • Of the 76 NSMs, 27 breasts received neo-adjuvant(20) or adjuvant chemotherapy and/or radiation(7) therapy. (aacrjournals.org)
  • The complications were seen in 11 in the non adjuvant treated setting (14%) and 9 (33%) in the adjuvant therapy setting. (aacrjournals.org)
  • Our results show there is a significant risk of wound complication associated with neo-adjuvant and adjuvant chemotherapy and radiation therapy in the setting of nipple sparing mastectomy. (aacrjournals.org)
  • Suggested improvements for the DA include: sequential presentation of treatment options (eg, no treatment vs 1 drug, 1 drug vs 2 drugs) to enhance patient understanding of the difference between combination and single therapy, diagrams to help patients understand the rationale for chemotherapy to prevent a recurrence and inbuilt checks on patient understanding of baseline risk of recurrence and net benefit of chemotherapy. (bmj.com)
  • A meta-analysis reported in The Lancet Oncology by the Early Breast Cancer Trialists' Collaborative Group indicates that neoadjuvant chemotherapy is associated with a higher local recurrence risk vs the same chemotherapy given postoperatively after breast-conserving therapy. (ascopost.com)
  • There were no significant differences between neoadjuvant chemotherapy and adjuvant therapy for 15-year distant recurrence (38.2% vs 38.0%, RR = 1.02, P = .66), breast cancer mortality (34.4% vs 33.7%, RR = 1.06, P = .31), or all-cause mortality (40.9% vs 41.2%, RR = 1.04, P = .45). (ascopost.com)
  • The investigators concluded: "Tumours downsized by [neoadjuvant chemotherapy] might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received [neoadjuvant chemotherapy]. (ascopost.com)
  • Yi-Long Wu, MD, FACS, Tenured Professor of the Lung Cancer Institute at Guangdong Provincial People's Hospital and Academy of Medical Sciences in Guangzhou, China, and a principal investigator in the ADAURA Phase III trial, said: "The overwhelming disease-free survival benefit in patients in ADAURA already supported the role of Tagrisso as a pioneering therapy in the adjuvant treatment of EGFR-mutated non-small cell lung cancer. (astrazeneca.se)
  • Of the 12 cases of AML/MDS in chemotherapy-treated patients, 8 patients had received anthracycline-containing therapy. (ascopost.com)
  • The aim of adjuvant therapy is to eradicate residual micrometastasis thus improving the cure rate in early stage. (esmo.org)
  • Identification of the highest-risk subset for adjuvant therapy still needs improvement. (esmo.org)
  • The multiinstitutional osteosarcoma study (MIOS), a randomized trial of adjuvant therapy for osteosarcoma with a concurrent control group, registered 113 patients from June 1982 to August 1984. (uni-bonn.de)
  • Six months of oxaliplatin-based chemotherapy has been the standard adjuvant therapy for stage III colon cancer since 2004. (ecancer.org)
  • Neither targeted therapy, nor predictors for chemotherapy sensitivity are available for triple-negative breast cancer (TNBC). (linkos.cz)
  • In line with the published data, adjuvant S-1 therapy has a tolerable toxicity profile among local patients who have undergone curative resection for gastric cancer. (hkmj.org)
  • For gastric cancer patients in whom adjuvant S-1 therapy is planned, close monitoring of those who have identifiable risk factors may enable early recognition of adverse events during therapy. (hkmj.org)
  • 3) reported on the prevalence and severity of long-term patient-reported PN in a cross-sectional study among patients who were within six and 24 months of completing adjuvant taxane therapy and in a small prospective study in patients initiating taxane therapy with longitudinal assessment up to 12 months after completing therapy. (deepdyve.com)
  • To determine whether the addition of cisplatin-based chemotherapy (CT) to pelvic radiation therapy (RT) will improve the survival of early-stage, high-risk patients with cervical carcinoma. (uni-bonn.de)
  • BCL11A copy number status could facilitate decision making on adjuvant therapy. (linkos.cz)
  • In patients with BCL11A deletion other types of adjuvant therapy should be considered. (linkos.cz)
  • citation needed] This systemic therapy (chemotherapy, immunotherapy or hormone therapy) or radiation therapy is commonly used in cancers that are locally advanced, and clinicians plan an operation at a later stage, such as pancreatic cancer. (wikipedia.org)
  • Treatment may consist of some combination of surgery, chemotherapy, and radiation therapy. (wikipedia.org)
  • In the Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) trial, a team of researchers from the European Organisation for Research and Treatment of Cancer (EORTC) randomly assigned 448 patients from across Europe to either adjuvant platinum-based chemotherapy or observation following surgery. (innovations-report.com)
  • The adjuvant chemotherapy consisted of an oral tegafur agent (OT) or platinum-based chemotherapy (PB). (dovepress.com)
  • Preclinical data suggest these tumors may be resistant to platinum-based chemotherapy. (sigmaaldrich.com)
  • Adjuvant platinum-based chemotherapy improves survival in patients with non-small cell lung cancer, but benefits only a minority of those treated. (aacrjournals.org)
  • Adjuvant platinum-based chemotherapy is a standard of care for patients with completely resected stage II to IIIA non-small cell lung cancer (NSCLC), with an absolute 5-year survival benefit of 4% to 15% in several randomized trials and meta-analyses ( 1-7 ). (aacrjournals.org)
  • At 5 years, there was no statistically significant difference in overall survival between patients who were treated with adjuvant chemotherapy and patients who were in the observation group. (innovations-report.com)
  • Similar to the ICON1 trial, the combined analysis found that 5-year overall survival was 8% greater in the adjuvant chemotherapy arm than in the observation arm. (innovations-report.com)
  • An adjuvant chemotherapy regimen improved overall survival in early-stage pancreatic cancer patients, in the large phase III European ESPAC-4 study reported at the 2016 ASCO Annual Meeting. (ascopost.com)
  • 1 Further, there was an early trend toward improved overall survival with adjuvant chemotherapy. (ascopost.com)
  • Small studies of systemic chemotherapy show a tantalizing hint of benefit in disease-free survival and overall survival, so we set out to explore this in a larger study," Dr. Birtle told listeners. (ascopost.com)
  • We sought to determine the overall survival benefit of chemotherapy among patients with stage II colon cancer having poor prognostic features. (pubmedcentralcanada.ca)
  • Among Medicare patients identified with stage II colon cancer, either with or without poor prognostic features, adjuvant chemotherapy did not substantially improve overall survival. (pubmedcentralcanada.ca)
  • Chemotherapy after surgery, known as adjuvant chemotherapy, led to higher rates of disease-free and overall survival for women with isolated local or regional recurrence of breast cancer. (oncologynurseadvisor.com)
  • Also, for this group, the overall survival was 79% for those who received chemotherapy and 69% for those who did not. (oncologynurseadvisor.com)
  • The ER-positive patients had an overall survival of 94% for those who received chemotherapy and 80% for those who did not. (oncologynurseadvisor.com)
  • Aim of our meta-analysis (MA): To assess the capacity of MSI status to predict the efficacy of adjuvant CT in terms of Overall Survival (OS) or Relapse Free Survival (RFS) in CRC, to study whenever possible the interaction between MSI status and prescription or not of CT. (aacrjournals.org)
  • Specifically, the manuscript describes the effectiveness of chemotherapy in improving overall survival after surgical resection in patients with stage II disease with no poor prognostic features, stage II disease with any poor prognostic features, and stage III disease. (esmo.org)
  • Exploratory analysis of the use of adjuvant chemotherapy in early-stage patients showed improved overall survival for patients whose tumors were ≥ 4 cm. (iaslc.org)
  • The results published in the Journal of Thoracic Oncology , the official journal of the International Association for the Study of Lung Cancer (IASLC), demonstrated that adjuvant chemotherapy was associated with improved median overall survival (OS) and 5-year OS compared to the observation group in both univariate (one variable) and multivariable (multiple variables) analyses. (iaslc.org)
  • Probability of death in pT4 patients receiving chemotherapy was lower compared to non-recipients (3-year overall survival 91% vs. 73%, HR 0.43, 95% CI 0.28-0.66). (eur.nl)
  • PURPOSE: A phase III trial (Cancer and Leukemia Group B CALGB-49907) was conducted to test whether older patients with early-stage breast cancer would have equivalent relapse-free and overall survival with capecitabine compared with standard chemotherapy. (druglib.com)
  • CONCLUSION: Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer. (druglib.com)
  • Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal cancer]. (sigmaaldrich.com)
  • We conducted a joint study of different duration of drug administration for oral adjuvant chemotherapy using camphor (HCFU) with patients having advanced colorectal cancer who underwent curative resection. (sigmaaldrich.com)
  • Surveillance Epidemiology, and End Results Program (SEER) show that only 48% of patients aged 65 to 74 years received adjuvant chemotherapy for node-positive colorectal cancer, and only 24% of those patients aged 80 to 84. (cancernetwork.com)
  • Benefit from 5-FU adjuvant chemotherapy depends on the MMR status of tumours in patients with colorectal cancer. (bmj.com)
  • Microsatellite instability status to predict efficacy of 5FU based adjuvant chemotherapy for colorectal cancer. (aacrjournals.org)
  • Material and Methods: Studies (full articles) were identified by an electronic search using online PubMed, with a set of keywords used simultaneously (colorectal neoplasm, chemotherapy, microsatellite instability, prognosis). (aacrjournals.org)
  • Objectives To develop a computerised decision aid (DA) to inform the decision process on adjuvant chemotherapy in patients with stage II colorectal cancer, and examine perceived usefulness, acceptability and areas for improvement of the DA. (bmj.com)
  • 1 , 2 One key issue for people who have undergone surgical resection of colorectal cancer is the decision about whether or not to have adjuvant chemotherapy, which is typically either 5-FU or capecitabine, given alone or in combination with oxaliplatin. (bmj.com)
  • The use of adjuvant chemotherapy in stage II colorectal cancer remains controversial in the oncology community. (esmo.org)
  • In this study, an inverse association was seen with chemotherapy and total Functional Assessment of Cancer Treatment (FACT)-General, FACT-Colorectal, physical, emotional, and functional well-being among patients with stage II colon cancer. (oncologynurseadvisor.com)
  • In those patients who achieved a complete surgical resection at interval debulking surgery, adjuvant treatment will include 3 cycles of durvalumab + chemotherapy and then a follow-up period. (clinicaltrials.gov)
  • Adjuvant chemotherapy after the complete resection of non-small-cell lung cancer (NSCLC) is now the standard of care. (dovepress.com)
  • Patients with clinical or pathological T4N0-2M0-stage tumours or perforated colon cancer were randomly assigned (1:1), with a web-based randomisation application, before resection of the primary tumotm to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy (experimental group) or to adjuvant systemic chemotherapy alone (control group). (rug.nl)
  • Expression was compared with histopathological evidence of response to chemotherapy after surgical resection. (bl.uk)
  • Adjuvant chemotherapy is typically considered for patients with stage II colon cancer characterized by poor prognostic features, including obstruction, perforation, emergent admission, T4 stage, resection of fewer than 12 lymph nodes, and poor histology. (pubmedcentralcanada.ca)
  • 3239 patients 23 to 86 years of age (median age 63 y, 61% men) with complete colon (71% of patients) or rectal (29%) cancer resection and an uncertain indication for adjuvant chemotherapy (as determined by consultation between attending physician and patient). (annals.org)
  • Several studies have found that patients with stage II and III NSCLC that had adjuvant chemotherapy following complete surgical resection lived longer than those that had surgery without chemotherapy. (iaslc.org)
  • However, in early-stage NSCLC patients there currently is not enough evidence to support the use of chemotherapy following complete resection, even though stage I lung cancer recurs either locally or at distant sites in roughly a third of early-stage patients. (iaslc.org)
  • A group of investigators analyzed a large cohort of patients (25,267) with pathologic stage T2N0M0 NSCLC, diagnosed from 2004 to 2011, and who underwent complete (R0) resection to evaluate the role of adjuvant chemotherapy in early-stage patients. (iaslc.org)
  • Patients with stage II-IIIC gastric adenocarcinoma who had undergone curative resection and who had received S-1 adjuvant chemotherapy were included in the study. (hkmj.org)
  • The aim of this study is to evaluate the laparoscopic method in gastric cancer staging before surgery in patients undergoing Neo-adjuvant chemotherapy. (degruyter.com)
  • Therefore, further investigation of more effective treatments is urgently needed.Several trials have been reported about adjuvant S1-combined chemotherapy for stage III gastric cancer. (ovid.com)
  • The aim of this study was to clarify the risk factors for discontinuing tegafur/gimeracil/oteracil potassium (S-1) adjuvant chemotherapy following gastrectomy in patients with gastric cancer. (jcancer.org)
  • We retrospectively investigated patients with curatively-resected gastric cancer who received S-1 adjuvant chemotherapy. (jcancer.org)
  • These results suggest that assessing renal function to avoid initial overdose of S-1, together with the early management of side effects, may support the continuation of S-1 adjuvant chemotherapy in patients with gastric cancer. (jcancer.org)
  • The use of adjuvant chemotherapy with S-1 (tegafur, gimeracil, and oteracil potassium) has been shown to improve the outcome of patients with gastric cancer. (hkmj.org)
  • Retrospective review of the clinical characteristics and clinical course of 735 patients with stages II and III primary breast cancer who were treated using three consecutive postoperative adjuvant chemotherapy protocols. (nih.gov)
  • To estimate the safety of the extremely early PAC, we evaluated the first post chemotherapy adverse reactions and defecation ability, and analyzed the variance laboratory indexes around the first postoperative adjuvant chemotherapy. (scirp.org)
  • An increasing proportion of patients with early-stage breast cancer are treated with taxanes as postoperative adjuvant chemotherapy. (spandidos-publications.com)
  • We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. (nih.gov)
  • Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer. (biomedsearch.com)
  • This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment compliance of the patients with advanced cervical squamous cell carcinoma. (biomedsearch.com)
  • We aimed to determine the efficacy of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced colon cancer. (rug.nl)
  • Certain models suggest that increasing the dose of this chemotherapy may enhance its efficacy. (bcaction.org)
  • ASCO GU 2020: The Efficacy of Two Cycles of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Patients. (urotoday.com)
  • This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. (centerwatch.com)
  • Although its medical efficacy is undeniable, the negative effects of adjuvant chemotherapy on cognitive functioning have been reported by some breast cancer patients, even years after treatment in some cases ( 3 - 9 ). (frontiersin.org)
  • Some physicians prescribe chemotherapy for these patients after their recurrent tumors have been completely removed by surgery, but the efficacy of this treatment has not been studied until now. (oncologynurseadvisor.com)
  • They reported adjuvant XELOX provides superior efficacy to surgery alone. (ovid.com)
  • MSI status, classified as MSI-high (MSI-H) or microsatellite stable (MSS) which also includes MSI-low, is considered a prognostic factor in CRC, but its ability to predict adjuvant chemotherapy (CT) efficacy is still controversial. (aacrjournals.org)
  • Sobrero said: "While overall there are minor differences in efficacy between three and six months, high risk patients should receive six months of chemotherapy and CAPOX should be preferred over FOLFOX. (ecancer.org)
  • In this study we investigate the feasibility and efficacy of this regimen in a neo-adjuvant setting. (eur.nl)
  • In a second trial, the International Collaborative Ovarian Neoplasm (ICON1) study, collaborators randomly assigned 477 patients to receive either adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer or no immediate adjuvant chemotherapy. (innovations-report.com)
  • Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. (cancerconnect.com)
  • While, based on these factors, researchers can't draw a definitive conclusion about the survival advantage of immediate adjuvant chemotherapy for treatment of bladder cancer, the evidence of a benefit may prove more useful when combined with data from similar studies. (cancerconnect.com)
  • Preliminary analysis of the study indicated a significant event-free survival advantage favoring immediate adjuvant chemotherapy, (P less than .001). (uni-bonn.de)
  • However, patients relapsing after treatment with surgery alone experienced a significantly longer interval to further disease progression (P less than .01) and improved survival after relapse (P = .01) when compared with patients who relapsed after treatment with immediate adjuvant chemotherapy. (uni-bonn.de)
  • To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) developed evidence-based recommendations for adjuvant chemotherapy for stage II colon cancer. (cancer.net)
  • Chemotherapy after surgery is not recommended for routine use in patients with stage II colon cancer. (cancer.net)
  • Adjuvant chemotherapy for stage II colon cancer may lower the risk of the cancer coming back, but is also associated with potentially serious side effects. (cancer.net)
  • To learn more about adjuvant chemotherapy for colon cancer, talk with your doctor about the stage of your cancer, your medical history, your overall health, and the risks and benefits of adjuvant treatment, including the potential side effects. (cancer.net)
  • CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients. (uptodate.com)
  • Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. (uptodate.com)
  • Patients with breast cancer may have adjuvant chemotherapy for as long as nine months, while patients with colon cancer may only need six months. (mercy.com)
  • Interpretation In patients with T4 or perforated colon cancer, treatment with adjuvant HIPEC with oxaliplatin did not improve peritoneal metastasis-free survival at 18 months. (rug.nl)
  • Currently, treatment with 5-FU plus leucovorin for 6 to 8 months is standard adjuvant treatment for patients with stage III colon cancer. (cancernetwork.com)
  • How long should Adjuvant Chemotherapy be given in Early Stage Colon Cancer? (omicsonline.org)
  • In May 2011, I published an editorial discussing my personal use of low dose, long term adjuvant chemotherapy for stage IIIc colon cancer in 1994-1997[ 1 ]. (omicsonline.org)
  • Thus this simple reasoning results in the conclusion that in order to be effective for all or nearly all cases, adjuvant chemotherapy for early stage colon cancer must be essentially nontoxic and used for over 2 years. (omicsonline.org)
  • In particular I will discuss here a reexamination of a long ago determined cancer therapeutic notion, i.e., the intensity and optimal duration of adjuvant chemotherapy after detection of early stage colon cancer. (omicsonline.org)
  • Despite its uncertain impact on survival, adjuvant chemotherapy administration is common, with one study identifying chemotherapy receipt among 27% of younger Medicare beneficiaries with stage II colon cancer. (pubmedcentralcanada.ca)
  • The authors conclude that the lack of benefit from chemotherapy must be considered in treatment decisions in patients over 65 years with colon cancer, with any possible survival benefit likely to be less than 2% at 5 years. (esmo.org)
  • Recurrence, survival, and quality of life (QOL) is not improved with adjuvant chemotherapy in most patients with stage II colon cancer, according to the results of a study published in Supportive Care in Cancer . (oncologynurseadvisor.com)
  • In this study, stage II colon cancer patients who received chemotherapy treatment were more likely to have poor QoL, recurrence, and all-cause mortality after 24 months compared to those who did not receive chemotherapy. (oncologynurseadvisor.com)
  • ESMO 2017: Debate on duration of colon cancer adjuvant chemotherapy takes centre stage at ESMO 2017. (ecancer.org)
  • The debate on whether to shorten adjuvant chemotherapy for colon cancer from six to three months takes centre stage today in a special session at the ESMO 2017 Congress in Madrid. (ecancer.org)
  • Is three months of chemotherapy enough in the adjuvant treatment of colon cancer? (ecancer.org)
  • A total of 4,940 of 10,935 patients with stage II colon cancer were identified as high risk, of whom 790 (16%) patients received adjuvant chemotherapy. (eur.nl)
  • In high-risk stage II colon cancer, adjuvant chemotherapy was associated with higher survival in pT4 only. (eur.nl)
  • To prevent unnecessary chemotherapy-induced toxicity, further refinement of patient subgroups within stage II colon cancer who could benefit from adjuvant chemotherapy seems indicated. (eur.nl)
  • Wednesday's General Session included a presentation on a large meta-analysis of 21,000 women in 16 randomized trials looking at early breast cancer and the use of adjuvant chemotherapy. (bcaction.org)
  • Adjuvant chemotherapy with anthracycline and taxane-based combinations for early breast cancer is known to reduce the risk of death from breast cancer by about one-third. (bcaction.org)
  • In another presentation Wednesday morning, Dr. Wolfgang Janni from the University of Ulm presented on the results of the SUCCESS trial on the use of adjuvant bisphosphonate treatment in high risk early breast cancer patients. (bcaction.org)
  • The researchers found that there was no significant difference in either DFS or OS between patients, irrespective of menopausal status, that received 2 or 5 years of zoledronate after adjuvant chemo for early breast cancer. (bcaction.org)
  • NICE has said that Oncotype DX is recommended to help make decisions about chemotherapy after surgery in some people with oestrogen receptor positive (ER+), lymph node negative (LN−) and human epidermal growth factor receptor 2 negative (HER2−) early breast cancer. (nice.org.uk)
  • Neoadjuvant chemotherapy was associated with a higher local recurrence rate in patients with early breast cancer. (ascopost.com)
  • The meta-analysis included patient-level data from 4,756 women from 10 randomized trials in early breast cancer that were started before 2005 and compared neoadjuvant chemotherapy with the same chemotherapy given postoperatively. (ascopost.com)
  • 1. Denduluri N: Risk of acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy for early breast cancer in the community setting. (ascopost.com)
  • We hypothesized that combination of data on genetic biomarkers with data from traditional clinical and pathophysiological (clinicopathologic) factors using traditional Cox model or Support Vector Machine (SVM) method, a new machine learning method, may provide a better tool for prediction of benefits to chemotherapy for the treatment of early breast cancer than using either biomarker or clinicopathologic data alone. (queensu.ca)
  • Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy. (bmj.com)
  • CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and long-term survival and local control rates of patients, improve the quality of life, and the toxicity can be tolerated. (biomedsearch.com)
  • Reasons for withholding adjuvant chemotherapy from elderly patients may include coexisting conditions, fear of toxicity, declining functional and mental status, and lack of social support, Dr. Sargent said, but "most people older than 75 are independent, and their life expectancy without cancer is 10 to 12 years. (cancernetwork.com)
  • The similarity in toxicity, he said, "is important, given the fact that one arm received combination chemotherapy. (ascopost.com)
  • This signature may enable more personalized approaches to the treatment of lung SCC, sparing chemotherapy toxicity and identifying patients for the evaluation of alternative therapeutic strategies. (aacrjournals.org)
  • Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection. (bioportfolio.com)
  • Neuropathy is a common complication that could result in chemotherapy dose reduction, but there is no evidence that this toxicity is associated with a higher risk of recurrence or inferior survival (6). (deepdyve.com)
  • We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2 (rIL-2) in patients with advanced (stage III-IV) head and neck squamous-cell carcinoma (HNSCC). (eurekamag.com)
  • The aim of this article was to summarize existing evidence on neoadjuvant and adjuvant chemotherapy in PDAC with a focus on high-level evidence based on randomized controlled phase III clinical trials. (springer.com)
  • In the early 1990s, two large randomized clinical trials were initiated to compare survival between patients treated with adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer and patients who received no additional treatments until clinically indicated. (innovations-report.com)
  • We evaluated the clinical relevance of these findings and assessed whether NRF2 activation predicts benefit from adjuvant chemotherapy in SCC. (sigmaaldrich.com)
  • Key eligibility criteria included age between 18 and 75 years, adequate clinical condition for HIPEC, and intention to start adjuvant systemic chemotherapy. (rug.nl)
  • These interesting observations will require prospective validation, but the possibility of refining the prognosis of individual patients and influencing clinical decisions regarding the use of adjuvant chemotherapy is an exciting prospect and should be evaluated in well-designed, prospective clinical trials such as the CALGB trial previously mentioned. (amazonaws.com)
  • Adjuvant chemotherapy should be considered a new standard of care," stated lead author Alison J. Birtle, MD , a clinical oncologist and Honorary Senior Lecturer at Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, United Kingdom. (ascopost.com)
  • Using this classifier, SCC patients with the activated signature treated in the JBR.10 clinical trial did not appear to derive benefit from chemotherapy. (aacrjournals.org)
  • A total of 260 patients with stage II or III tumours received 5-FU adjuvant chemotherapy, according to standard clinical criteria and irrespective of their MMR status. (bmj.com)
  • Among women randomized to receive neoadjuvant chemotherapy, 69% had a complete or partial clinical response. (ascopost.com)
  • Consequently, a thorough investigation of the clinical benefits and survival of the use of adjuvant chemotherapy in early-stage patients is warranted in order to improve the current treatment recommendations. (iaslc.org)
  • In low risk patients the difference was so minor that the clinical conclusion is that three months of oxaliplatin-based chemotherapy is as good as six months," said Van Cutsem. (ecancer.org)
  • To develop a health economic model to assess the cost-effectiveness of these tests compared with clinical tools to guide the use of adjuvant chemotherapy in early-stage breast cancer from the perspective of the NHS and Personal Social Services. (whiterose.ac.uk)
  • Only one completed randomised controlled trial (RCT) using a tumour profiling test in clinical practice was identified: Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT) for MammaPrint. (whiterose.ac.uk)
  • 3.4 (clinical intermediate risk), evidence surrounding pre- and post-test chemotherapy probabilities is subject to considerable uncertainty. (whiterose.ac.uk)
  • In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management interventions, tai chi training and spiritual growth groups, were compared to a usual care control group, to evaluate psychosocial functioning, quality of life (QOL), and biological markers thought to reflect cancer- and treatment-specific mechanisms. (hindawi.com)
  • Large operable T2-T3 breast cancer (BC), treated with neoadjuvant chemotherapy, may theoretically appear suitable for this surgical option, alternative to conventional mastectomy or breast conserving surgery in case of unfavorable size of the breast, when a good response to neoadjuvant chemotherapy has been achieved. (clinicaltrials.gov)
  • Both the population of patients treated with neoadjuvant chemotherapy (NAC-PC and PC groups) were T2-T3 N0-N1 breast cancer. (clinicaltrials.gov)
  • One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (nih.gov)
  • Adjuvant chemotherapy and neoadjuvant chemotherapy are frequently used in the treatment of breast, colon, lung, bladder, and prostate cancers. (rockymountaincancercenters.com)
  • Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. (nih.gov)
  • To determine whether obesity is an independent prognostic factor among women receiving adjuvant chemotherapy for lymph node-positive breast cancer and to determine how obesity relates to other commonly used prognostic indicators. (nih.gov)
  • Obesity is an indicator of poor prognosis for patients with primary breast cancer even after the administration of adjuvant chemotherapy. (nih.gov)
  • Evaluate your overall health - if you are otherwise healthy, you are more likely to benefit from adjuvant chemotherapy for breast cancer. (mercy.com)
  • How you respond to treatment - if your doctor thinks you can tolerate the side effects associated with chemotherapy, he or she is more likely to recommend adjuvant chemotherapy as a part of your breast cancer treatment plan. (mercy.com)
  • When successful, adjuvant chemotherapy reduces the risk of breast cancer recurrence by 35 percent for women under 50 and by 20 percent in women over 50 years old. (mercy.com)
  • There are a variety of factors in play when evaluating the potential success of adjuvant chemotherapy for breast cancer treatment. (mercy.com)
  • Dosing and the duration of adjuvant chemotherapy was a prominent theme in the first two days of the San Antonio Breast Cancer Symposium (SABCS). (bcaction.org)
  • Adjuvant chemotherapy is a very common treatment for breast cancer patients-it's what patients are given after primary treatments, such as surgery or radiation. (bcaction.org)
  • Retrospective studies have demonstrated a worse outcome in breast cancer patients not developing leukopenia during adjuvant chemotherapy. (bioportfolio.com)
  • A meta-analysis was performed to quantify the magnitude and nature of the association between adjuvant chemotherapy and performance on a range of cognitive domains among breast cancer patients. (frontiersin.org)
  • Results suggested that cognitive impairment is present among breast cancer patients irrespective of a history of chemotherapy. (frontiersin.org)
  • Accurate understanding of the effects of chemotherapy is essential to enable informed decisions regarding treatment and to improve quality of life among breast cancer patients. (frontiersin.org)
  • Adjuvant chemotherapy increases the survival rate in breast cancer patients and is currently administered to up to 60% of patients below the age of 60 years ( 2 ). (frontiersin.org)
  • To support informed decision making, it is important to understand the magnitude and specific areas of cognitive impairment that breast cancer patients may experience after adjuvant chemotherapy. (frontiersin.org)
  • An increasing number of studies have examined the effects of adjuvant chemotherapy for breast cancer on cognitive functioning ( 10 - 13 ). (frontiersin.org)
  • The study involved the Breast International Group, the National Surgical Adjuvant Breast and Bowel Project, and the International Breast Cancer Study Group. (oncologynurseadvisor.com)
  • The greatest benefit occurred in women with estrogen receptor (ER)-negative breast cancer, whose 5-year survival rate was 67% among those who received chemotherapy and 69% among those who did not. (oncologynurseadvisor.com)
  • To investigate the timeliness of initiation of adjuvant chemotherapy following surgery for breast cancer, we used data from the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database. (springer.com)
  • Among women ≥ 65 years diagnosed between 1992 and 1999 with stages I-II breast cancer, we used linear regression and Cox proportional hazards models to investigate the time intervals between surgery and initiation of adjuvant chemotherapy, factors associated with delay, and the effect of delay on survival. (springer.com)
  • Because taxanes exhibit incomplete cross-resistance with anthracyclines, and adjuvant anthracycline chemotherapy still leaves considerable residual risk of disease recurrence and death from breast cancer, multiple trials are addressing the value of incorporating taxanes, either sequentially or in combination with anthracyclines, in an effort to improve outcomes ( 8 , 9 ). (aacrjournals.org)
  • She outlines the background and design of the trial, which is a large prospective trial, investigating the 70-gene signature MammaPrint to guide the use of adjuvant chemotherapy in breast cancer patients. (ecancer.org)
  • Contradicting what some previous investigations have found, a study from The US Oncology Network found that adjuvant chemotherapy for breast cancer does not increase the risk of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS), at least within the first 3 years of treatment. (ascopost.com)
  • Anthracycline-based chemotherapies for breast cancer are known to adversely affect patients' quality of life (QOL) and immune function. (spandidos-publications.com)
  • Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis. (physiciansweekly.com)
  • Triple-negative breast cancer (TNBC) is known for its higher recurrence rate in short-term (3-5 years) follow-up and limited systemic therapeutic methods (chemotherapy). (physiciansweekly.com)
  • Our main results showed that breast cancer recurrence rate in T1a/bN0 TNBC patients receiving chemotherapy was significantly lower than those without chemotherapy (OR 0.54, 95% CI 0.37-0.78, P = 0.001). (physiciansweekly.com)
  • We evaluated the contribution of an epirubicin-based adjuvant chemotherapy on disease-free survival (DFS) in poor prognosis, node-negative breast cancer (BC) patients. (jle.com)
  • Methods The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer. (deepdyve.com)
  • Adjuvant chemotherapy (AC) improves survival among patients with operable breast cancer. (biomedcentral.com)
  • Adjuvant chemotherapy (AC) is routinely recommended to most of breast cancer patients post surgeries. (biomedcentral.com)
  • Clinically, 60-80% of breast cancer patients would ultimately receive AC, but the optimal time from surgery to the start of chemotherapy is unclear albeit clinicians have used chemotherapy in breast cancer for more than a half century. (biomedcentral.com)
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. (druglib.com)
  • Individual tumour foci treated with laser hyperthermia were also coded for laser parameters including power settings, number of treatments, and concomitant administration of systemic chemotherapy (chemothermotherapy). (bmj.com)
  • Laser settings, number of hyperthermia treatments, and the concomitant use of systemic chemotherapy (chemothermotherapy) were not associated with higher rates of vitreous relapse. (bmj.com)
  • The study was done to test the hypothesis that adjacent use of lasers with systemic chemotherapy for treatment of retinoblastoma may reduce recurrence rates while also causing local side effects. (physiciansweekly.com)
  • Systemic chemotherapy alone was used in 71 eyes while chemotherapy plus laser was used in 20 eyes. (physiciansweekly.com)
  • This contrasted with the results of a Canadian study that showed significantly improved 5-year survival for stage IB and II patients treated with adjuvant cisplatin-vinorelbine for 4 cycles. (medscape.com)
  • Patients with resected stage IB NSCLC should, therefore, be counseled about risks and benefits of adjuvant chemotherapy and may be offered either 4 cycles of platinum-based doublet chemotherapy, preferably cisplatin, or observation. (medscape.com)
  • Some adjuvant chemotherapy is administered in a few treatment cycles while others are administered for up to 10 years. (rockymountaincancercenters.com)
  • Zhang J, Huang Y, Sun Y, He A, Zhou Y, Hu H, Yao Y, Shen Z. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. (harvard.edu)
  • In the PB group, the percentage of patients who completed the four planned cycles of chemotherapy was not correlated with the PNI. (dovepress.com)
  • Within 90 days postsurgery, patients were randomized 1:1 to receive 4 cycles of gemcitabine-based chemotherapy or surveillance. (ascopost.com)
  • Compliance was considered good: About 70% received all four planned cycles of chemotherapy. (ascopost.com)
  • Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study," Gynecologic Oncology , vol. 100, no. 1, pp. 27-32, 2006. (hindawi.com)
  • Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view," The Oncologist , vol. 13, no. 4, pp. 410-414, 2008. (hindawi.com)
  • Adjuvant chemotherapy is additional treatment given after surgery to lower the risk of the cancer returning. (cancer.net)
  • Chemotherapy is the use of drugs to treat cancer. (cancer.net)
  • However, chemotherapy can damage healthy cells along with cancer cells. (cancer.net)
  • In other words, patients who receive chemotherapy after surgery have a very small chance of reducing the risk of their cancer coming back compared with patients who do not receive the extra treatment. (cancer.net)
  • Results from two large European studies suggest that adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer can increase some patients chances of both overall and recurrence-free survival. (innovations-report.com)
  • In an accompanying editorial, Robert C. Young, M.D., of the Fox Chase Cancer Center in Philadelphia, says that the trials add important information on adjuvant chemotherapy but do not address which patients can be spared unnecessary adjuvant chemotherapy. (innovations-report.com)
  • What is the role of adjuvant chemotherapy in non-small cell lung cancer (NSCLC)? (medscape.com)
  • Adjuvant chemotherapy is given after surgery for early stage cancer. (springer.com)
  • The objective is mainly to explore the safety and feasibility in neo-adjuvant first-line ovarian cancer (including patients with primary peritoneal or fallopian tube adenocarcinoma) of various combinations of durvalumab with chemotherapy with or without tremelimumab. (clinicaltrials.gov)
  • Chemotherapy is often used alongside surgery to treat cancer. (rockymountaincancercenters.com)
  • If your cancer treatment plan includes adjuvant chemotherapy or neoadjuvant chemotherapy, that means you will be receiving both chemotherapy and surgery to treat your cancer. (rockymountaincancercenters.com)
  • Chemotherapy is the use of powerful drugs to kill or slow the growth of cancer cells. (rockymountaincancercenters.com)
  • Adjuvant chemotherapy is administered after surgery to kill any remaining cancer cells with the goal of reducing the chances of recurrence. (rockymountaincancercenters.com)
  • If your cancer treatment plan includes neoadjuvant chemotherapy, you are likely to begin chemotherapy very quickly so that surgery can be performed. (rockymountaincancercenters.com)
  • A research team of the European Organisation for Research and Treatment of Cancer (EORTC) selected patients from four EORTC-trials which were coordinated by Professor C.J.H. van de Velde from the Leiden University Medical Center, to study the effect of chemotherapy in young women. (science20.com)
  • However, long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected non-small-cell lung cancer indicated a possible late adjuvant chemotherapy-related over-mortality. (biomedsearch.com)
  • Adjuvant chemotherapy is a cancer treatment that combines different healing therapies to maximize benefit for the patient. (mercy.com)
  • The goal of adjuvant chemotherapy is to eliminate any remaining cancer cells that are not detected and may have traveled to other parts of the body. (mercy.com)
  • What types of cancer is adjuvant chemotherapy used for? (mercy.com)
  • Depending on the type of cancer, adjuvant chemotherapy will begin three to five weeks after surgery to remove the cancerous tissue. (mercy.com)
  • Chemotherapy treatment length will vary based on the type of cancer you have. (mercy.com)
  • Your Mercy Health cancer care team will evaluate your case to determine if you are a candidate for adjuvant chemotherapy. (mercy.com)
  • Likelihood of your cancer recurring - if you have a type of cancer that is likely to recur, your doctor may strongly recommend adjuvant chemotherapy. (mercy.com)
  • If you are in an early stage where the cancer has not spread, adjuvant chemotherapy may not be necessary. (mercy.com)
  • Intraperitoneal chemotherapy (IP) is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer (EOC), according to initial results from the randomized phase II OV21/PETROC trial reported at the 2016 ASCO Annual Meeting. (onclive.com)
  • This looked at women with advanced ovarian cancer, all of whom received primary chemotherapy before surgery, and in that group of women, we have not known what the best strategy is. (onclive.com)
  • Those findings sparked controversy at the time and left both patients and doctors "scratching their heads," according to the Ovarian Cancer Research Fund, which advised patients, in a statement issued after GOG 252's findings were announced, not to "abandon IP chemotherapy. (onclive.com)
  • The findings show that patients who can undergo surgery have a fighting chance of surviving this cancer with the combination of two commonly used chemotherapies. (ascopost.com)
  • Based on a 5-year survival rate of 29% with this combination, he said, "Adjuvant gemcitabine with capecitabine is the standard of care for resected pancreatic cancer. (ascopost.com)
  • Adjuvant gemcitabine with capecitabine is the next step change for resected pancreatic cancer," he said at an ASCO press briefing. (ascopost.com)
  • ADJUVANT CHEMOTHERAPY achieved robust improvements in disease-free survival and metastasis-free survival compared with surveillance in the phase III POUT study of patients with upper tract urothelial cancer. (ascopost.com)
  • Standard treatment for upper tract urothelial cancer is radical nephro-urectomy followed by surveillance, with chemotherapy given when needed. (ascopost.com)
  • Because, in historical series, at least 10% of patients thought to have upper tract urothelial cancer turn out not to have cancer when the surgical specimen is biopsied, and another 10% to 15% have low-grade disease, there is a risk of overtreatment with neoadjuvant chemotherapy, which has also been proposed for this disease," she explained. (ascopost.com)
  • In the phase III POUT trial, adjuvant chemotherapy significantly improved disease-free survival and metastasis-free survival compared with surveillance and chemotherapy given at relapse in patients with upper tract urothelial cancer. (ascopost.com)
  • For patients with this type of cancer, the standard of care is treatment with chemotherapy. (mesothelioma.com)
  • 1 - 10 The commonly cited Quick and Simple and Reliable (QUASAR) prospective trial reported a pooled relative risk (RR) of death of 0.82 (95% CI, 0.70 to 0.95) for patients with stage I to III colon and rectal cancer receiving chemotherapy compared with surgery alone. (pubmedcentralcanada.ca)
  • Scher HI (1990) Chemotherapy for invasive bladder cancer: neo-adjuvant vs. adjuvant. (springer.com)
  • Tannock I (1990) The current status of adjuvant chemotherapy for bladder cancer. (springer.com)
  • 1987) Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. (springer.com)
  • Conclusion: Addition of adjuvant chemotherapy to radiation improves progression-free survival in operated endometrial cancer patients with no residual tumour and a high-risk profile. (diva-portal.org)
  • however, interviews showed that there was evidence of a lack of understanding of key information among some patients, in particular their baseline risk of recurrence, the net benefit of combination chemotherapy and the rationale for having chemotherapy when cancer had apparently gone. (bmj.com)
  • In our institution, adjuvant RT is proposed to patients with resected extrahepatic biliary tract cancer presenting with unfavorable features. (biomedcentral.com)
  • Results from an exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) extended disease-free survival (DFS) in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) regardless of prior adjuvant chemotherapy treatment or stage of disease, building on the unprecedented primary DFS results for Tagrisso in the adjuvant setting announced last year . (astrazeneca.se)
  • Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "These new data show that Tagrisso provides transformative benefits independent of prior chemotherapy treatment, preventing lung cancer from returning while allowing patients to sustain their quality of life. (astrazeneca.se)
  • Following the recent approval of Tagrisso in the US in the adjuvant setting, we continue to work urgently with regulatory authorities globally to bring this new standard of care to patients with early-stage lung cancer. (astrazeneca.se)
  • In addition, significantly higher odds of cancer recurrence were seen among those patients who received chemotherapy. (oncologynurseadvisor.com)
  • A randomized double‑blind study was conducted to evaluate the effectiveness of Lentinula edodes mycelia extract (LEM), which is an oral biological response modifier (BRM) medicine for cancer patients as such an adjuvant. (spandidos-publications.com)
  • In gastrointestinal cancer patients undergoing chemotherapy, oral LEM exerted an inhibitory effect on the incidence of adverse events (AEs), such as chemotherapy-induced nausea, and also improved immune function, by increasing natural killer (NK) cell activity, resulting in improvement of the patients' QOL ( 20 , 21 ). (spandidos-publications.com)
  • This study investigates the effectiveness of omega-3 fatty acids on the completion rate of adjuvant chemotherapy for biliary tract cancer (BTC). (bmj.com)
  • When you think about disease that's so aggressive and has a high risk of recurrence, you want to give more aggressive chemotherapy. (onclive.com)
  • Therefore, this study assessed prognostic value of these subtypes in additional patient cohorts along with associations with risk of recurrence and response to chemotherapy. (doaj.org)
  • In conclusion, histological phenotypic subtypes are an effective prognostic classification in patients with stage III CRC that associates with risk of recurrence and response to FOLFOX adjuvant chemotherapy. (doaj.org)
  • A variety of studies have shown that postoperative chemotherapy significantly improves the 5-year survival rate and reduces the risk of recurrence or metastasis. (scirp.org)
  • Adjuvant chemotherapy is the use of drugs to eradicate or suppress residual disease after surgery or irradiation has been used to treat the tumour. (britannica.com)
  • From January 2009 to May 2013, 422 BC patients were progressively accrued to NAC-sparing mastectomy, of which 361 invasive BC patients underwent NAC-sparing mastectomy as first treatment (NAC-group), whereas 61 T2-T3 invasive BC patients underwent surgery after primary chemotherapy (NAC-PC group). (clinicaltrials.gov)
  • In arm A, the tremelimumab will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. (clinicaltrials.gov)
  • If your treatment plan includes adjuvant chemotherapy, you'll likely begin treatments within 30 days following surgery. (rockymountaincancercenters.com)
  • We know that the recurrence of the disease is so high that I try to give adjuvant treatment if I can to all the patients after surgery. (onclive.com)
  • Typically, chemotherapy is used after radiation and/or surgery. (mercy.com)
  • Two randomized phase III trials in N2-positive patients (stage IIIA) failed to show any survival benefit for surgery following induction chemotherapy or chemoradiotherapy compared with chemoradiotherapy alone,3,4 thereby making the role of routine surgery in this subset of NSCLC questionable. (amazonaws.com)
  • In all adjuvant settings, significant numbers of patients receive treatment who would have otherwise been cured by surgery alone. (amazonaws.com)
  • She added that the use of neoadjuvant chemotherapy has increased in recent years, with approximately 40% of women with EOC receiving chemotherapy prior to surgery. (onclive.com)
  • The aim of OV21/PETROC was to determine whether this group of patients, who typically undergo more chemotherapy after surgery, would benefit from having that chemotherapy delivered intraperitoneally. (onclive.com)
  • In the UK, it is standard practice to treat oesophageal adenocarcinoma with neo-adjuvant chemotherapy (no radiation) and surgery. (bl.uk)
  • Survival did not differ among patients who initiated chemotherapy within 1, 2, or 3 months after surgery. (springer.com)
  • The addition of adjuvant or neoadjuvant chemotherapy to surgery revolutionises the treatment of high-grade non-metastatic osteosarcoma of the extremities. (fmshk.com.hk)
  • This study evaluated a pool of periampullary tumors (ampulla, duodenum and distal bile duct cancers) and showed no benefit in adding adjuvant chemo-radiation to surgery. (biomedcentral.com)
  • For patients treated with surgery alone or with surgery and adjuvant chemotherapy, the lungs were involved in more than 80% of the relapses. (uni-bonn.de)
  • Patients relapsing after surgery alone tended to relapse earlier (P less than .01), had more pulmonary nodules (P less than .01), and had more frequent bilateral pulmonary involvement (P less than .01) than those treated with immediate postsurgical adjuvant chemotherapy. (uni-bonn.de)
  • 5-FU adjuvant chemotherapy improves survival in patients with MMR competent tumours but this benefit from chemotherapy cannot be extended to patients with MMR deficient tumours. (bmj.com)
  • In multivariate analyses, p53 was confirmed as an independent factor predictive of benefit from FOLFOX (P = 0.03), while the interaction of MSI with chemotherapy could not be determined in the absence of relapse in the MSI group treated with FOLFOX. (uptodate.com)
  • If the stage indicates relatively high risk of relapse, adjuvant chemotherapy is used for 6 or so months to reduce the probability of such relapse. (omicsonline.org)
  • Ongoing research is evaluating the benefits of beginning adjuvant chemotherapy immediately following cystectomy or waiting until signs of relapse (deferred chemotherapy). (cancerconnect.com)
  • a deferred-treatment group received six rounds of chemotherapy at signs of relapse. (cancerconnect.com)
  • Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor? (bmj.com)
  • To evaluate rates of vitreous relapse among retinoblastoma patients treated with primary chemotherapy and assess diode laser as a potential risk factor for relapse. (bmj.com)
  • Eyes that developed vitreous relapse were coded with regard to Reese-Ellsworth Group, laterality, time to relapse, type of relapse (vitreous base or non-vitreous base relapse), treatments used (including adjuvant diode laser), and ocular preservation. (bmj.com)
  • Mean time to relapse was 7.2 months after chemotherapy was completed. (bmj.com)
  • Nearly one in seven eyes with retinoblastoma treated with primary chemotherapy may develop vitreous relapse. (bmj.com)
  • Macular relapse rates were similar between groups: 22/71 (31%) eyes in the chemotherapy group and 9/20 (45%) eyes in the laser group (p=0.29). (physiciansweekly.com)
  • Tumour profiling tests aim to identify whether or not women need chemotherapy owing to their risk of relapse. (whiterose.ac.uk)
  • 10 LNs evaluated, no association between receipt of adjuvant chemotherapy and survival was observed. (eur.nl)
  • Conclusions Methods of measuring these biomarkers should be considered and developed to aid individualised treatment plans for patients with oesophageal adenocarcinoma and predict response to chemotherapy. (bl.uk)
  • This study evaluated patient acceptability, perceived usefulness and understanding of a decision aid (DA) using mixed-methods at the point patients made their decision about whether or not to have adjuvant chemotherapy. (bmj.com)
  • 1985) Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. (springer.com)
  • 1989) Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. (springer.com)
  • However, recurrence-free survival was statistically significantly improved, with 76% of patients treated with adjuvant chemotherapy surviving without a recurrence, compared with 68% of patients in the observation arm. (innovations-report.com)
  • 50 before adjuvant chemotherapy was significantly poorer than that of the patients with a PNI ≥50. (dovepress.com)
  • Furthermore, the immune subtype significantly associated with better response to FOLFOX compared to CAPOX adjuvant chemotherapy in stage III patients (p = 0.013). (doaj.org)
  • Chemotherapy was significantly superior to surveillance in subgroups of nodal involvement, planned type of chemotherapy, microscopic margin, and disease stage (with a similar hazard ratio for benefit seen across all subgroups). (ascopost.com)
  • Conclusion: Among MSI-H patients compared with MSS, adjuvant CT was associated with a significantly better survival. (aacrjournals.org)
  • The study found that women who received part of their adjuvant chemotherapy regimen using the IP approach had nearly a 19% reduction in progressive disease, compared with their counterparts whose chemotherapy was delivered only intravenously. (onclive.com)
  • 1985) Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract, a northern California Oncology Group study. (springer.com)
  • So I treat my patients with capecitabine, and if a patient is within advanced disease, meaning more lymph nodes affected, probably I treat the patient with gemcitabine-based chemotherapy with no randomized data. (onclive.com)
  • The quality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better QoL than standard chemotherapy. (druglib.com)
  • The absence of BCL2 expression in prechemotherapy samples is associated with a higher probability of pathological complete response to neoadjuvant doxorubicin-based chemotherapy. (linkos.cz)
  • BCL2 expression could facilitate decision making on adjuvant treatment in TNBC patients. (linkos.cz)
  • Conclusions Patients found the DA acceptable and useful in supporting their decision about whether or not to have adjuvant chemotherapy. (bmj.com)
  • Conclusions: The comparable prevalence of CTCs at the time of last chemotherapy cycle may indicate that anthracycline-free chemotherapy is equally effective to anthracycline-containing chemotherapy in HER2-negative, hormone receptor-positive EBC. (uni-muenchen.de)
  • Adjuvant chemotherapy has been extensively explored in NSCLC. (medscape.com)
  • Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all? (biomedsearch.com)
  • Adjuvant chemotherapy improves disease-free survival and metastasis-free survival. (ascopost.com)
  • For the primary endpoint of 3-year disease-free survival rate, chemotherapy had a strong benefit: 71% in the chemotherapy group vs 54% in the surveillance group, representing a 51% improvement that was statistically significant (P = .001). (ascopost.com)
  • For patients with ER-positive disease, the 5-year disease-free survival was 70% for those who received chemotherapy and 69% for those who did not. (oncologynurseadvisor.com)
  • Dr. Birtle is the Chief Investigator of the POUT study and presents the side of adjuvant chemotherapy for the standard of care in patients with upper tract urothelial carcinoma. (urotoday.com)
  • I think adjuvant chemotherapy should be the standard of care for many patients with upper tract urothelial carcinomas. (urotoday.com)
  • The team will determine if the benefits of receiving treatment outweighs the survival rate without adjuvant chemotherapy. (mercy.com)
  • In response to questions about choosing neoadjuvant or adjuvant chemotherapy now, Dr. Neoptolemos stated that the benefit of neoadjuvant chemotherapy has not been established in randomized studies. (ascopost.com)
  • In this paper, the literature is reviewed to explore the existence of any comparative benefit of neoadjuvant over adjuvant chemotherapy for this disease entity. (fmshk.com.hk)
  • This meta-analysis aimed to compare short-term recurrence rate between patients receiving adjuvant chemotherapy or not for this population. (physiciansweekly.com)
  • Our results revealed that adjuvant chemotherapy reduced recurrence rate for T1mi/a/bN0 TNBC, especially for T1bN0. (physiciansweekly.com)
  • Impact of adjuvant chemotherapy on oncologic outcmoes following radical nephroureterectomy for patients with pT3anyM0 upper tract urothelial carcinoma: A retrospective cohort study. (renalandurologynews.com)
  • Thus, given the small number and the retrospective nature of published single institution studies, the impact of adjuvant RT has not been yet clarified. (biomedcentral.com)